EP4175639B1 - Masitinib for the treatment of castrate-resistant prostate cancer - Google Patents
Masitinib for the treatment of castrate-resistant prostate cancer Download PDFInfo
- Publication number
- EP4175639B1 EP4175639B1 EP22733858.9A EP22733858A EP4175639B1 EP 4175639 B1 EP4175639 B1 EP 4175639B1 EP 22733858 A EP22733858 A EP 22733858A EP 4175639 B1 EP4175639 B1 EP 4175639B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- masitinib
- pharmaceutically acceptable
- acceptable salt
- solvate
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- WJEOLQLKVOPQFV-UHFFFAOYSA-N masitinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3SC=C(N=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 WJEOLQLKVOPQFV-UHFFFAOYSA-N 0.000 title claims description 166
- 239000002139 L01XE22 - Masitinib Substances 0.000 title claims description 158
- 229960004655 masitinib Drugs 0.000 title claims description 158
- 238000011282 treatment Methods 0.000 title claims description 139
- 208000000236 Prostatic Neoplasms Diseases 0.000 title claims description 38
- 206010060862 Prostate cancer Diseases 0.000 title claims description 37
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 156
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 156
- 150000003839 salts Chemical class 0.000 claims description 99
- 238000004393 prognosis Methods 0.000 claims description 96
- 239000012453 solvate Substances 0.000 claims description 83
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims description 76
- 239000000556 agonist Substances 0.000 claims description 57
- 108700012941 GNRH1 Proteins 0.000 claims description 39
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims description 37
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims description 37
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 claims description 37
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims description 30
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 30
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 claims description 29
- 229960000853 abiraterone Drugs 0.000 claims description 27
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 claims description 27
- 229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 claims description 27
- 238000001794 hormone therapy Methods 0.000 claims description 27
- 239000013543 active substance Substances 0.000 claims description 17
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 15
- 230000001394 metastastic effect Effects 0.000 claims description 14
- 102000001554 Hemoglobins Human genes 0.000 claims description 12
- 108010054147 Hemoglobins Proteins 0.000 claims description 12
- 208000037911 visceral disease Diseases 0.000 claims description 12
- 239000002246 antineoplastic agent Substances 0.000 claims description 9
- 229940127089 cytotoxic agent Drugs 0.000 claims description 9
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
- 101710088194 Dehydrogenase Proteins 0.000 claims description 4
- 239000004310 lactic acid Substances 0.000 claims description 4
- 235000014655 lactic acid Nutrition 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 3
- -1 for example Substances 0.000 description 71
- 239000000902 placebo Substances 0.000 description 54
- 229940068196 placebo Drugs 0.000 description 54
- 125000001072 heteroaryl group Chemical group 0.000 description 21
- 125000003118 aryl group Chemical group 0.000 description 20
- 238000000034 method Methods 0.000 description 19
- 230000008901 benefit Effects 0.000 description 18
- 230000000694 effects Effects 0.000 description 16
- 230000004044 response Effects 0.000 description 16
- 125000001424 substituent group Chemical group 0.000 description 16
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 15
- 229960003668 docetaxel Drugs 0.000 description 15
- 125000000217 alkyl group Chemical group 0.000 description 14
- 230000003381 solubilizing effect Effects 0.000 description 14
- 230000004083 survival effect Effects 0.000 description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 13
- 206010028980 Neoplasm Diseases 0.000 description 11
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 10
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 10
- 125000003545 alkoxy group Chemical group 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 229910052736 halogen Inorganic materials 0.000 description 10
- 150000002367 halogens Chemical class 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 125000000753 cycloalkyl group Chemical group 0.000 description 9
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 9
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 9
- 229960004618 prednisone Drugs 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 125000005842 heteroatom Chemical group 0.000 description 8
- 125000003277 amino group Chemical group 0.000 description 7
- 239000003098 androgen Substances 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 230000036407 pain Effects 0.000 description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 238000009167 androgen deprivation therapy Methods 0.000 description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 125000004663 dialkyl amino group Chemical group 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 125000000623 heterocyclic group Chemical group 0.000 description 6
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 6
- 125000002950 monocyclic group Chemical group 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 206010027476 Metastases Diseases 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 125000004093 cyano group Chemical group *C#N 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 125000001188 haloalkyl group Chemical group 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 229960003604 testosterone Drugs 0.000 description 5
- 206010061818 Disease progression Diseases 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000005750 disease progression Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000004907 gland Anatomy 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 125000004193 piperazinyl group Chemical group 0.000 description 4
- 125000003386 piperidinyl group Chemical group 0.000 description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 230000009278 visceral effect Effects 0.000 description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
- 229940030486 androgens Drugs 0.000 description 3
- 125000003710 aryl alkyl group Chemical group 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 description 3
- 125000005117 dialkylcarbamoyl group Chemical group 0.000 description 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229950002475 mesilate Drugs 0.000 description 3
- 125000002757 morpholinyl group Chemical group 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 201000001474 proteinuria Diseases 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 2
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 2
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 2
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 2
- 125000005986 4-piperidonyl group Chemical group 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 206010027457 Metastases to liver Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 230000002280 anti-androgenic effect Effects 0.000 description 2
- 239000000051 antiandrogen Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 description 2
- 229960001573 cabazitaxel Drugs 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 125000005945 imidazopyridyl group Chemical group 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 239000002050 international nonproprietary name Substances 0.000 description 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 108010087599 lactate dehydrogenase 1 Proteins 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 229960003646 lysine Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 125000003566 oxetanyl group Chemical group 0.000 description 2
- 125000000466 oxiranyl group Chemical group 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 125000005017 substituted alkenyl group Chemical group 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 125000004426 substituted alkynyl group Chemical group 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- 230000002618 waking effect Effects 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- AOMXMOCNKJTRQP-UHFFFAOYSA-N 1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea Chemical compound C1=CC(NC(=O)NOC)=CC=C1C1=C(CN(C)C)C(C(=O)N(C=2N=NC(OC)=CC=2)C(=O)N2CC=3C(=CC=CC=3F)F)=C2S1 AOMXMOCNKJTRQP-UHFFFAOYSA-N 0.000 description 1
- 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- 125000003562 2,2-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003660 2,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003764 2,4-dimethylpentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- YGTUPRIZNBMOFV-UHFFFAOYSA-N 2-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=C(O)C=C1 YGTUPRIZNBMOFV-UHFFFAOYSA-N 0.000 description 1
- KKFDCBRMNNSAAW-UHFFFAOYSA-N 2-(morpholin-4-yl)ethanol Chemical compound OCCN1CCOCC1 KKFDCBRMNNSAAW-UHFFFAOYSA-N 0.000 description 1
- RZUKHJWGZWHLAB-UHFFFAOYSA-N 2-(thian-2-ylsulfinyl)thiane Chemical compound C1CCCSC1S(=O)C1CCCCS1 RZUKHJWGZWHLAB-UHFFFAOYSA-N 0.000 description 1
- KFXDYZXVIHNBFD-UHFFFAOYSA-N 2-(thian-2-ylsulfonyl)thiane Chemical compound C1CCCSC1S(=O)(=O)C1CCCCS1 KFXDYZXVIHNBFD-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- PKRSYEPBQPFNRB-UHFFFAOYSA-N 2-phenoxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1OC1=CC=CC=C1 PKRSYEPBQPFNRB-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004337 3-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- RXXCIBALSKQCAE-UHFFFAOYSA-N 3-methylbutoxymethylbenzene Chemical compound CC(C)CCOCC1=CC=CC=C1 RXXCIBALSKQCAE-UHFFFAOYSA-N 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 229940127512 Androgen Synthesis Inhibitors Drugs 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003671 Atrioventricular Block Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010061728 Bone lesion Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000014526 Conduction disease Diseases 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 101710141452 Major surface glycoprotein G Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000023146 Pre-existing disease Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 229910006074 SO2NH2 Inorganic materials 0.000 description 1
- 206010040736 Sinoatrial block Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 108010052004 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide Proteins 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 239000003936 androgen receptor antagonist Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229960002272 degarelix Drugs 0.000 description 1
- MEUCPCLKGZSHTA-XYAYPHGZSA-N degarelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CC=1C=CC(NC(=O)[C@H]2NC(=O)NC(=O)C2)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(NC(N)=O)C=C1 MEUCPCLKGZSHTA-XYAYPHGZSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229950010286 diolamine Drugs 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229940044170 formate Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 229950000177 hibenzate Drugs 0.000 description 1
- 108700020746 histrelin Proteins 0.000 description 1
- 229960002193 histrelin Drugs 0.000 description 1
- HHXHVIJIIXKSOE-QILQGKCVSA-N histrelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 HHXHVIJIIXKSOE-QILQGKCVSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000005946 imidazo[1,2-a]pyridyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- TXCWBWKVIZGWEQ-UHFFFAOYSA-N methanesulfonic acid;4-[(4-methylpiperazin-1-yl)methyl]-n-[4-methyl-3-[(4-pyridin-3-yl-1,3-thiazol-2-yl)amino]phenyl]benzamide Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3SC=C(N=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 TXCWBWKVIZGWEQ-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005487 naphthalate group Chemical group 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229950004864 olamine Drugs 0.000 description 1
- 238000011474 orchiectomy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 125000000394 phosphonato group Chemical group [O-]P([O-])(*)=O 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229950004238 relugolix Drugs 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 125000006092 tetrahydro-1,1-dioxothienyl group Chemical group 0.000 description 1
- 125000005888 tetrahydroindolyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000004305 thiazinyl group Chemical group S1NC(=CC=C1)* 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- WCNFFKHKJLERFM-UHFFFAOYSA-N thiomorpholinyl sulfone group Chemical group N1(CCSCC1)S(=O)(=O)N1CCSCC1 WCNFFKHKJLERFM-UHFFFAOYSA-N 0.000 description 1
- ZCAGUOCUDGWENZ-UHFFFAOYSA-N thiomorpholinyl sulfoxide group Chemical group N1(CCSCC1)S(=O)N1CCSCC1 ZCAGUOCUDGWENZ-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
- 206010047302 ventricular tachycardia Diseases 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the present invention relates to the treatment of prostate cancer, in particular of castrate-resistant prostate cancer (CRPC).
- CRPC castrate-resistant prostate cancer
- Prostate cancer is one of the most common cancers in men. There were an estimated 1,414,259 new cases of prostate cancer diagnosed worldwide in 2020, representing 7.3% of the estimated total new cancer cases ( Sung H et al. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660 ).
- the incidence rate based on the 2013-2017 data, was 104.6 new cases per 100,000 men per year (American Cancer Society, 2018 - Data sources: North American Association of Central Cancer Registries (NAACCR), 2020).
- NAACCR North American Association of Central Cancer Registries
- the average incidence rate was estimated in 2018 at 151.2 new cases per 100,000 men, with an average death rate estimated the same year at 32.8 per 100,000 ( Hofmarcher, T et al. (2019) Comparator Report on Cancer in Europe 2019 - Disease Burden, Costs and Access to Medicines. IHE Report 2019:7. IHE: Lund, Swed en).
- Prostate cancer is driven by male sex hormones called androgens, including testosterone and dihydrotestosterone (DHT). Hormone therapy, aiming either at decreasing androgen levels or blocking androgen action, can inhibit the growth of prostate cancer.
- hormone therapy aiming either at decreasing androgen levels or blocking androgen action, can inhibit the growth of prostate cancer.
- ADT androgen deprivation therapy
- ADT thus includes surgical castration (i.e., orchiectomy) and chemical (or medical) castration.
- Chemical castration may be obtained through the administration of luteinizing hormone-releasing hormone (LHRH) agonists, sometimes called LHRH analogs, or through the administration of LHRH antagonists.
- LHRH luteinizing hormone-releasing hormone
- LHRH is also sometimes called gonadotropin-releasing hormone (GnRH) and, accordingly, LHRH agonists (or analogs) are also known as GnRH agonists (or analogs), and LHRH antagonists as GnRH antagonists.
- GnRH gonadotropin-releasing hormone
- Castrate-resistant prostate cancer is defined by disease progression despite androgen deprivation therapy and may present as either a continuous rise in serum prostate-specific antigen (PSA) levels, the progression of pre-existing disease, and/or the appearance of new metastases ( Saad et al. Can Urol Assoc J. 2010 Dec;4(6):380-4 ).
- Treatment options then comprise further hormone therapies, such as antiandrogen therapies including androgen receptor blockers and androgen synthesis inhibitors (for example abiraterone), immunotherapy, and chemotherapy, in particular docetaxel or cabazitaxel.
- mCRPC metastatic castrate- (or castration-) resistant prostate cancer
- compositions comprising Masitinib for use in the treatment of mCRPC.
- mCRPC metastatic castrate-(or castration-) resistant prostate cancer
- the present invention thus relates to masitinib, or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of metastatic castrate-resistant prostate cancer (mCRPC) in a subject in need thereof, in particular in a subject most likely to benefit from the administration of masitinib, or a pharmaceutically acceptable salt or solvate thereof, such as a subject having alkaline phosphatase levels at baseline equal to or lower than 250 IU/L and/or with a Halabi prognosis score (H) at baseline equal to or lower than 33.
- mCRPC metastatic castrate-resistant prostate cancer
- the present invention relates to masitinib, or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of metastatic castrate-resistant prostate cancer (mCRPC) in a subject in need therefore, wherein said subject suffers from early mCRPC associated (i) with alkaline phosphatase (ALP) levels at baseline equal to or lower than 250 IU/L, or (ii) with a Halabi prognosis score (H) at baseline equal to or lower than 33, or (iii) with ALP levels at baseline equal to or lower than 250 IUAL and with a Halabi prognosis score (H) at baseline equal to or lower than 33, as defined in the appended claims.
- ALP alkaline phosphatase
- H Halabi prognosis score
- H Halabi prognosis score
- said subject has ALP levels at baseline equal to or lower than 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L. In one embodiment, said subject has ALP levels at baseline equal to or lower than 200 IU/L. In one embodiment, said subject has ALP levels at baseline equal to or lower than 150 IU/L. In one embodiment, said subject has ALP levels at baseline equal to or lower than 100 IU/L.
- said subject has a Halabi prognosis score (H) at baseline equal to or lower than 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15. In one embodiment, said subject has a Halabi prognosis score (H) at baseline equal to or lower than 22.
- said subject received hormone therapy selected from the group consisting of luteinizing hormone-releasing hormone (LHRH) agonists (also known as gonadotropin-releasing hormone (GnRH) agonists), LHRH antagonists (also known as GnRH antagonists), and abiraterone.
- LHRH luteinizing hormone-releasing hormone
- GnRH gonadotropin-releasing hormone
- abiraterone abiraterone
- the pharmaceutically acceptable salt of masitinib is masitinib mesilate.
- masitinib, or a pharmaceutically acceptable salt or solvate thereof is for administration at a dose ranging from about 1 to about 12 mg/kg/day (mg per kilo body weight per day), preferably at a dose ranging from about 3 to about 6 mg/kg/day. In one embodiment, masitinib, or a pharmaceutically acceptable salt or solvate thereof, is for administration at a dose of about 6 mg/kg/day.
- masitinib, or a pharmaceutically acceptable salt or solvate thereof is for oral administration. In one embodiment, masitinib, or a pharmaceutically acceptable salt or solvate thereof, is for administration in two daily intakes.
- masitinib, or a pharmaceutically acceptable salt or solvate thereof is for administration with at least one further pharmaceutically active agent.
- said at least one further pharmaceutically active agent is selected from chemotherapeutic agents and corticoids.
- ALP refers to alkaline phosphatase.
- ALP is a membrane-bound glycoprotein which catalyzes the hydrolysis of organic phosphate esters present in the extracellular space.
- ALP is ubiquitous and can be found in a number of different tissues (such as, for example, placenta, intestine, kidney, bone, and liver) from which it is released in the blood.
- ALP levels refer to ALP levels in the blood, in particular in the serum.
- Baseline refers to the time preceding the start of treatment with a 2-aminoarylthiazole derivative, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, as described herein.
- ALP levels at baseline are the ALP levels prior to the administration to the subject of a 2-aminoarylthiazole derivative, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, as described herein.
- the Halabi prognosis score (H) at baseline is the Halabi prognosis score (H) prior to the administration to the subject of a 2-aminoarylthiazole derivative, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, as described herein.
- “Pharmaceutically acceptable excipient” or “pharmaceutically acceptable carrier” refers to an excipient or carrier that does not produce an adverse, allergic or other untoward reaction when administered to a subject. It includes any and all solvents, such as, for example, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents.
- a pharmaceutically acceptable excipient or carrier refers to a non-toxic solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
- preparations should meet sterility, pyrogenicity, general safety and purity standards as required by the regulatory offices such as the FDA (U.S. food and drug administration) or EMA (European medicines agency).
- Subject refers to a mammal, preferably a human.
- the mammal is selected from cats, dogs, cows, pigs, horses, monkeys, apes and humans.
- the mammal is selected from cats, dogs and humans.
- the subject is a primate.
- the subject is a human.
- the subject may be a "patient", i.e., a mammal, preferably a human, who/which is awaiting the receipt of, or is receiving medical care or was/is/will be the object of a medical procedure, or is monitored for the development of prostate cancer.
- a "subject in need of treatment” is a subject who is awaiting the receipt of, or is receiving medical care, or was/is/will be the object of a medical procedure, or is monitored for the development of prostate cancer, in particular metastatic castrate-resistant prostate cancer (mCRPC).
- mCRPC metastatic castrate-resistant prostate cancer
- “Therapeutically effective amount” or “therapeutically effective dose” refers to the amount or concentration of a 2-aminoarylthiazole derivative as described herein, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, that is aimed at, without causing significant negative or adverse side effects to the subject in need of treatment, bringing about at least one of the following: (1) slowing down or stopping the progression, aggravation, or deterioration of one or more symptom(s) of castrate-resistant prostate cancer (CRPC), in particular mCRPC, and notably prolonging survival of the subject, in particular progression-free survival; (2) bringing about ameliorations of the symptoms of CRPC, in particular mCRPC; (3) reducing the severity or incidence of CRPC, in particular mCRPC; (4) decreasing prostate specific antigen (PSA) levels (e.g., by at least 30% from baseline PSA levels), (5) curing CRPC, in particular mCRPC, (6) increasing quality of life or (7) decreasing pain intensity.
- Treating” or “Treatment” refers to a therapeutic treatment, to a prophylactic (or preventative) treatment, or to both a therapeutic treatment and a prophylactic (or preventative) treatment, wherein the object is to prevent, reduce, or slow down (lessen) one or more of the symptom(s) or manifestation(s) of castrate-resistant prostate cancer (CRPC), in particular of mCRPC.
- CRPC castrate-resistant prostate cancer
- a subject is successfully "treated" for CRPC, in particular mCRPC, if, after receiving a therapeutic amount of a 2-aminoarylthiazole derivative as described herein, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, the subject shows observable and/or measurable reduction in the number or percent of cancer cells or metastatic cells; and/or if the subject shows relief to some extent of one or more of the symptoms associated with CRPC, in particular of mCRPC; reduced PSA levels; reduced pain; reduced morbidity and mortality; and/or improvement in quality of life issues.
- a 2-aminoarylthiazole derivative as described herein, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof the subject shows observable and/or measurable reduction in the number or percent of cancer cells or metastatic cells; and/or if the subject shows relief to some extent of one or more of the symptoms associated with CRPC, in particular of mCRPC; reduced PSA levels
- a subject is successfully "treated” for CRPC, in particular mCRPC, if, after receiving a therapeutic amount of a 2-aminoarylthiazole derivative as described herein, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, the subject benefits from an extended survival, in particular of an extended progression-free survival.
- CRPC in particular mCRPC
- the present invention relates to a 2-aminoarylthiazole derivative as described herein, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of prostate cancer in a subject in need thereof as defined hereinafter.
- the prostate cancer is metastatic prostate cancer, in particular metastatic castrate-resistant prostate cancer (mCRPC).
- mCRPC metastatic castrate-resistant prostate cancer
- the subject in need of treatment has alkaline phosphatase (ALP) levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L.
- ALP alkaline phosphatase
- the subject prior to treatment with a 2-aminoarylthiazole derivative as described herein, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, the subject has ALP levels equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L.
- ALP levels are well-known to one skilled in the art and include, for example, the alkaline phosphatase isoenzyme blood test.
- ALP levels are expressed in IU/L (international units per liter) or in microkatals per liter ( ⁇ kat/L).
- the normal range of ALP levels in human healthy adults is generally considered to be about 44 to about 147 IU/L.
- ALP levels are often elevated in subjects suffering from prostate cancer (including CRPC), in particular in subjects suffering from metastatic prostate cancer (including mCRPC). ALP levels can thus reach up to about 1000 - 3000 IU/L in human subjects suffering from metastatic prostate cancer (including mCRPC).
- the subject in need of treatment has ALP levels at baseline equal to or lower than 250 IU/L. In one embodiment, the subject in need of treatment has ALP levels at baseline equal to or lower than 200 IU/L. In one embodiment, the subject in need of treatment has ALP levels at baseline equal to or lower than 150 IU/L. In one embodiment, the subject in need of treatment has ALP levels at baseline equal to or lower than 100 IU/L.
- the subject in need of treatment has a Halabi prognosis score (H) at baseline equal to or lower than 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15.
- H Halabi prognosis score
- the subject prior to treatment with a 2-aminoarylthiazole derivative as described herein, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, the subject has a Halabi prognosis score (H) equal to or lower than 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15.
- H Halabi prognosis score
- Halabi prognosis score is based on the method described by Halabi et al. (J Clin Oncol. 2003 Apr 1;21(7) 1232-7 ).
- the Halabi prognosis score (H) as defined herein is obtained with a mathematic formula used to model and estimate patient survival, which is based on the measurement of visceral disease (yes or no, the value of this parameter being equal to 1 if the subject is affected with visceral disease, and 0 if he is not), initial Gleason score (the value being equal to 1 if the Gleason score measured for the subject ranges from 8 to 10, and 0 if the Gleason score is inferior to 8), ECOG (Eastern Cooperative Oncology Group) performance status (ranging from 0 to 2), prostate specific antigen (PSA) levels (PSA, measured in ng/mL), lactic acid dehydrogenase (LDH) levels (LDH, measured in IU/L), alkaline phosphatase (ALP) levels (ALP or AP, measured in IU/L) and hemoglobin (HB, measured in g/dL).
- PSA prostate specific antigen
- LDH lactic acid
- ECOG is for Eastern Cooperative Oncology Group status and corresponds to a scale published in 1982 ( Oken et al., Am J Clin Oncol. 1982;5:649-655 ) and describing a patient's level of functioning in terms of their ability to care for themself, daily activity, and physical ability (walking, working, etc.).
- the ECOG performance status comprises 6 grades, from 0 (fully active, able to carry on all pre-disease performance without restriction) to 5 (dead).
- the ECOG performance status of the subject ranges from 0 to 2.
- the subject has an ECOG performance status of 0 or 1
- the Gleason score is a prognostic score for prostate cancer patients, obtained from prostate biopsy samples based on the microscopic appearance. The score ranges from 2 to 10, with higher numbers indicating greater risks and higher mortality. For measuring the score, two patterns are measured, the first one based on the dominant or most common cell morphology (scored 1-5) and the second one based on the non-dominant cell pattern (also scored 1-5). The two patterns are thus combined to obtain a score ranging from 2 to 10. Gleason's patterns are the following: 1 - small, uniform glands, 2 - more stroma between glands, 3 - distinctly infiltrative margins, 4 - irregular masses of neoplastic glands, and 5 - only occasional gland formation.
- Visceral disease is a clinical manifestation of metastatic CRPC, corresponding to the presence of metastasis, predominantly in the lung and liver.
- LDH lactic acid dehydrogenase
- ALP or AP alkaline phosphatase
- PSA prostate specific antigen
- HB hemoglobin
- the subject in need of treatment has a Halabi prognosis score (H) at baseline equal to or lower than 33. In one embodiment, the subject in need of treatment has a Halabi prognosis score (H) at baseline equal to or lower than 27. In one embodiment, the subject in need of treatment has a Halabi prognosis score (H) at baseline equal to or lower than 22. In one embodiment, the subject in need of treatment has a Halabi prognosis score (H) at baseline equal to or lower than 21. In one embodiment, the subject in need of treatment has a Halabi prognosis score (H) at baseline equal to or lower than 19. In one embodiment, the subject in need of treatment has a Halabi prognosis score (H) at baseline equal to or lower than 18.
- the subject in need of treatment has a Halabi prognosis score (H) at baseline equal to or lower than 17. In one embodiment, the subject in need of treatment has a Halabi prognosis score (H) at baseline equal to or lower than 16. In one embodiment, the subject in need of treatment has a Halabi prognosis score (H) at baseline equal to or lower than 15.
- the subject in need of treatment was previously treated by castration treatment, corresponding to the reduction of available androgen, testosterone or dihydrotestosterone (DHT), by chemical or surgical means.
- castration treatment corresponding to the reduction of available androgen, testosterone or dihydrotestosterone (DHT), by chemical or surgical means.
- the subj ect in need of treatment received hormone therapy selected from the group consisting of luteinizing hormone-releasing hormone (LHRH) agonists (also known as gonadotropin-releasing hormone (GnRH) agonists), LHRH antagonists (also known as GnRH antagonists), and abiraterone.
- LHRH luteinizing hormone-releasing hormone
- GnRH gonadotropin-releasing hormone
- LHRH antagonists also known as GnRH antagonists
- abiraterone prior to treatment with a 2-aminoarylthiazole derivative as described herein, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof
- the subject prior to treatment with a 2-aminoarylthiazole derivative as described herein, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, the subject received hormone therapy selected from the group consisting of LHRH agonists (also known as GnRH agonists), LHRH
- the subject in need of treatment previously received LHRH agonists (also known as GnRH agonists).
- LHRH agonists include, but are not limited to, leuprolide, goserelin, triptorelin and histrelin.
- the subject in need of treatment previously received LHRH antagonists (also known as GnRH antagonists).
- LHRH antagonists include, but are not limited to, degarelix and relugolix.
- the subject in need of treatment previously received abiraterone.
- the subject was previously treated by surgical castration.
- the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15.
- ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L
- H Halabi prognosis score
- the subject in need of treatment has ALP levels at baseline equal to or lower than 250 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15.
- the subject in need of treatment has ALP levels at baseline equal to or lower than 200 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15.
- the subject in need of treatment has ALP levels at baseline equal to or lower than 150 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15.
- the subject in need of treatment has ALP levels at baseline equal to or lower than 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15.
- the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 33.
- the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 27.
- the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 22.
- the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 21.
- the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 20.
- the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 19.
- the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 18.
- the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 17.
- the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 16.
- the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 15.
- the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and received hormone therapy selected from the group consisting of luteinizing hormone-releasing hormone (LHRH) agonists (also known as gonadotropin-releasing hormone (GnRH) agonists), LHRH antagonists (also known as GnRH antagonists), and abiraterone.
- LHRH luteinizing hormone-releasing hormone
- GnRH gonadotropin-releasing hormone
- the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 200, 150, or 100 IU/L, and received hormone therapy selected from the group consisting of LHRH agonists (also known as GnRH agonists), LHRH antagonists (also known as GnRH antagonists), and abiraterone.
- LHRH agonists also known as GnRH agonists
- LHRH antagonists also known as GnRH antagonists
- abiraterone abiraterone
- Halabi prognosis score at baseline equal to or lower than 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15, and received hormone therapy selected from the group consisting of LHRH agonists (also known as GnRH agonists), LHRH antagonists (also known as GnRH antagonists), and abiraterone.
- the subject in need of treatment has a Halabi prognosis score (H) at baseline equal to or lower than 33, 27, 22, 21, 20, 19, 18, 17, 16, or 15, and received hormone therapy selected from the group consisting of LHRH agonists (also known as GnRH agonists), LHRH antagonists (also known as GnRH antagonists), and abiraterone.
- H Halabi prognosis score
- the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L; and a Halabi prognosis score (H) at baseline equal to or lower than 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15; and received hormone therapy selected from the group consisting of LHRH agonists (also known as GnRH agonists), LHRH antagonists (also known as GnRH antagonists), and abiraterone.
- LHRH agonists also known as GnRH agonists
- LHRH antagonists also known as GnRH antagonists
- abiraterone abiraterone
- the subject in need of treatment has ALP levels at baseline equal to or lower than 250 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15; and received hormone therapy selected from the group consisting of LHRH agonists (also known as GnRH agonists), LHRH antagonists (also known as GnRH antagonists), and abiraterone.
- LHRH agonists also known as GnRH agonists
- LHRH antagonists also known as GnRH antagonists
- abiraterone abiraterone
- the subject in need of treatment has ALP levels at baseline equal to or lower than 200 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15; and received hormone therapy selected from the group consisting of LHRH agonists (also known as GnRH agonists), LHRH antagonists (also known as GnRH antagonists), and abiraterone.
- LHRH agonists also known as GnRH agonists
- LHRH antagonists also known as GnRH antagonists
- abiraterone abiraterone
- the subject in need of treatment has ALP levels at baseline equal to or lower than 150 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15; and received hormone therapy selected from the group consisting of LHRH agonists (also known as GnRH agonists), LHRH antagonists (also known as GnRH antagonists), and abiraterone.
- LHRH agonists also known as GnRH agonists
- LHRH antagonists also known as GnRH antagonists
- abiraterone abiraterone
- the subject in need of treatment has ALP levels at baseline equal to or lower than 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15; and received hormone therapy selected from the group consisting of LHRH agonists (also known as GnRH agonists), LHRH antagonists (also known as GnRH antagonists), and abiraterone.
- LHRH agonists also known as GnRH agonists
- LHRH antagonists also known as GnRH antagonists
- abiraterone abiraterone
- the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 33; and received hormone therapy selected from the group consisting of LHRH agonists (also known as GnRH agonists), LHRH antagonists (also known as GnRH antagonists), and abiraterone.
- LHRH agonists also known as GnRH agonists
- LHRH antagonists also known as GnRH antagonists
- abiraterone abiraterone
- the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 27; and received hormone therapy selected from the group consisting of LHRH agonists (also known as GnRH agonists), LHRH antagonists (also known as GnRH antagonists), and abiraterone.
- LHRH agonists also known as GnRH agonists
- LHRH antagonists also known as GnRH antagonists
- abiraterone abiraterone
- the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 22; and received hormone therapy selected from the group consisting of LHRH agonists (also known as GnRH agonists), LHRH antagonists (also known as GnRH antagonists), and abiraterone.
- LHRH agonists also known as GnRH agonists
- LHRH antagonists also known as GnRH antagonists
- abiraterone abiraterone
- the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 21; and received hormone therapy selected from the group consisting of LHRH agonists (also known as GnRH) agonists, LHRH antagonists (also known as GnRH antagonists), and abiraterone.
- LHRH agonists also known as GnRH
- LHRH antagonists also known as GnRH antagonists
- abiraterone abiraterone
- the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 20; and received hormone therapy selected from the group consisting of LHRH agonists (also known as GnRH agonists), LHRH antagonists (also known as GnRH antagonists), and abiraterone.
- LHRH agonists also known as GnRH agonists
- LHRH antagonists also known as GnRH antagonists
- abiraterone abiraterone
- the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 19; and received hormone therapy selected from the group consisting of LHRH agonists (also known as GnRH agonists), LHRH antagonists (also known as GnRH antagonists), and abiraterone.
- LHRH agonists also known as GnRH agonists
- LHRH antagonists also known as GnRH antagonists
- abiraterone abiraterone
- the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 18; and received hormone therapy selected from the group consisting of LHRH agonists (also known as GnRH agonists), LHRH antagonists (also known as GnRH antagonists), and abiraterone.
- LHRH agonists also known as GnRH agonists
- LHRH antagonists also known as GnRH antagonists
- abiraterone abiraterone
- the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 17; and received hormone therapy selected from the group consisting of LHRH agonists (also known as GnRH agonists), LHRH antagonists (also known as GnRH antagonists), and abiraterone.
- LHRH agonists also known as GnRH agonists
- LHRH antagonists also known as GnRH antagonists
- abiraterone abiraterone
- the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 16; and received hormone therapy selected from the group consisting of LHRH agonists (also known as GnRH agonists), LHRH antagonists (also known as GnRH antagonists), and abiraterone.
- LHRH agonists also known as GnRH agonists
- LHRH antagonists also known as GnRH antagonists
- abiraterone abiraterone
- the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 15; and received hormone therapy selected from the group consisting of LHRH agonists (also known as GnRH agonists), LHRH antagonists (also known as GnRH antagonists), and abiraterone.
- LHRH agonists also known as GnRH agonists
- LHRH antagonists also known as GnRH antagonists
- abiraterone abiraterone
- mCRPC early metastatic castrate-resistant prostate cancer
- ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L
- H Halabi prognosis score
- H Halabi prognosis score
- the subject in need of treatment suffers from early mCRPC associated (i) with ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, or (ii) with a Halabi prognosis score (H) at baseline equal to or lower than 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15, or (iii) with ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L and with a Halabi prognosis score (H) at baseline equal to or lower than 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32,
- mCRPC associated with ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L or with a Halabi prognosis score (H) at baseline equal to or lower than 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15.
- H Halabi prognosis score
- the subject in need of treatment suffers from early mCRPC associated with ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L and with a Halabi prognosis score (H) at baseline equal to or lower than 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15.
- H Halabi prognosis score
- the subject in need of treatment suffers from early mCRPC associated with ALP levels at baseline equal to or lower than 250 IU/L and/or with a Halabi prognosis score (H) at baseline equal to or lower than 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15.
- H Halabi prognosis score
- the subject in need of treatment suffers from early mCRPC associated with ALP levels at baseline equal to or lower than 200 IU/L and/or with a Halabi prognosis score (H) at baseline equal to or lower than 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15.
- H Halabi prognosis score
- the subject in need of treatment suffers from early mCRPC associated with ALP levels at baseline equal to or lower than 150 IU/L and/or with a Halabi prognosis score (H) at baseline equal to or lower than 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15.
- H Halabi prognosis score
- the subject in need of treatment suffers from early mCRPC associated with ALP levels at baseline equal to or lower than 100 IU/L and/or with a Halabi prognosis score (H) at baseline equal to or lower than 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15.
- H Halabi prognosis score
- the subject in need of treatment suffers from early mCRPC associated with ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 33.
- the subject in need of treatment suffers from early mCRPC associated with ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 27.
- the subject in need of treatment suffers from early mCRPC associated with ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 22.
- the subject in need of treatment suffers from early mCRPC associated with ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) baseline equal to or lower than 21.
- the subject in need of treatment suffers from early mCRPC associated with ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 20.
- the subject in need of treatment suffers from early mCRPC associated with ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 19.
- the subject in need of treatment suffers from early mCRPC associated with ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 18.
- the subject in need of treatment suffers from early mCRPC associated with ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 17.
- the subject in need of treatment suffers from early mCRPC associated with ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 16.
- the subject in need of treatment suffers from early mCRPC associated with ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 15.
- the subject in need of treatment suffers from early mCRPC as defined hereinabove and received (preferably before the initiation of the treatment with a 2-aminoarylthiazole derivative as described herein) hormone therapy selected from the group consisting of luteinizing hormone-releasing hormone (LHRH) agonists (also known as gonadotropin-releasing hormone (GnRH) agonists), LHRH antagonists (also known as GnRH antagonists), and abiraterone.
- LHRH luteinizing hormone-releasing hormone
- GnRH gonadotropin-releasing hormone
- abiraterone also known as gonadotropin-releasing hormone (GnRH) agonists
- the subject in need of treatment is an adult.
- an adult is a subject above the age of 18, 19, 20, or 21 years.
- the subject in need of treatment is older than 20, 25, or 30 years.
- the subject in need of treatment is a child.
- a child is a subject below the age of 21, 20, 19, or 18 years.
- the subject in need of treatment has an ECOG performance status of 0 or 1. In another embodiment, the subject in need of treatment has an ECOG performance status of 2.
- the subject is receiving androgen deprivation therapy selected from the group consisting of luteinizing hormone-releasing hormone (LHRH) agonists (also known as gonadotropin-releasing hormone (GnRH) agonists) and LHRH antagonists (also known as GnRH antagonists).
- LHRH luteinizing hormone-releasing hormone
- GnRH gonadotropin-releasing hormone
- GnRH antagonists also known as GnRH antagonists
- a 2-aminoarylthiazole derivative refers to a compound characterized by the presence of a thiazolyl group substituted on position 2 (i.e., between the heterocyclic nitrogen and sulfur atoms) by a secondary or tertiary amine, wherein the nitrogen atom of the amine is substituted by at least one aryl group.
- the aryl group is substituted by an arylamide group (i.e., NH CO aryl).
- the 2-aminoarylthiazole derivative disclosed or a pharmaceutically acceptable salt or solvate thereof is a 2-aminoarylthiazole derivative of formula (I) or a pharmaceutically acceptable salt or solvate thereof.
- R 1 of formula (II) is a solubilizing group. In one embodiment, R 1 of formula (II) is (C 1 -C 10 ) alkyl substituted by a solubilizing group.
- R 1 of formula (II) is (C 1 -C 10 ) alkyl-(C 2 -C 11 ) heterocycloalkyl-(C 1 -C 10 ) alkyl-. In one embodiment, R 1 of formula (II) is (C 1 -C 4 ) alkyl-(C 2 -C 11 ) heterocycloalkyl-(C 1 -C 10 ) alkyl-, preferably (C 1 -C 2 ) alkyl-(C 2 -C 11 ) heterocycloalkyl-(C 1 -C 10 ) alkyl-.
- R 1 of formula (II) is (C 1 -C 10 ) alkyl-(C 2 -C 11 ) heterocycloalkyl-(C 1 -C 4 ) alkyl-, preferably (C 1 -C 10 ) alkyl-(C 2 -C 11 ) heterocycloalkyl-(C 1 -C 2 ) alkyl-.
- R 1 of formula (II) is (C 1 -C 10 ) alkyl-(C 2 -C 6 ) heterocycloalkyl-(C 1 -C 10 ) alkyl-, preferably (C 1 -C 10 ) alkyl-(C 4 ) heterocycloalkyl-(C 1 -C 10 ) alkyl-.
- R 1 of formula (II) is (C 1 -C 4 ) alkyl-(C 2 -C 6 ) heterocycloalkyl-(C 1 -C 4 ) alkyl-, preferably (C 1 -C 2 ) alkyl-(C 4 ) heterocycloalkyl-(C 1 -C 2 ) alkyl-.
- R 1 of formula (II) is (C 1 -C 4 ) alkyl-piperazinyl-(C 1 -C 4 ) alkyl-, preferably (C 1 -C 2 ) alkyl-piperazinyl-(C 1 -C 2 ) alkyl-.
- R 1 of formula (II) is methylpiperazinyl-(C 1 -C 2 ) alkyl-, preferably methylpiperazinyl-methyl-, more preferably 4-methylpiperazinyl-methyl-.
- the 2-aminoarylthiazole derivative disclosed or a pharmaceutically acceptable salt or solvate thereof is a 2-aminoarylthiazole derivative of formula (II) as described above or a pharmaceutically acceptable salt or solvate thereof.
- aryl group refers to a polyunsaturated, aromatic hydrocarbyl group having a single aromatic ring ( i . e ., phenyl) or multiple aromatic rings fused together (e.g., naphtyl) or linked covalently, typically containing 5 to 12 atoms; preferably 6 to 10, wherein at least one ring is aromatic.
- the aromatic ring may optionally include one to two additional rings (either cycloalkyl, heterocyclyl or heteroaryl) fused thereto.
- Aryl is also intended to include the partially hydrogenated derivatives of the carbocyclic systems enumerated herein.
- Suitable aryl groups include, without being limited to, phenyl, tolyl, anthracenyl, fluorenyl, indenyl, azulenyl, and naphthyl, as well as benzo-fused carbocyclic moieties such as 5,6,7,8-tetrahydronaphthyl.
- An aryl group can be unsubstituted or substituted with one or more substituents.
- the aryl group is a monocyclic ring, wherein the ring comprises 6 carbon atoms, referred to herein as "(C 6 ) aryl".
- alkyl group refers to a saturated straight chain or branched non-cyclic hydrocarbon having from 1 to 10 carbon atoms, preferably from 1 to 6 carbon atoms.
- Representative saturated straight chain alkyls include, without being limited to, methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl and n-decyl.
- Saturated branched alkyls include, without being limited to, isopropyl, sec-butyl, isobutyl, tert-butyl, isopentyl, 2-methylbutyl, 3-methylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2,3-dimethylbutyl, 2,3-dimethylpentyl, 2,4-dimethylpentyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylpentyl, 2,2-dimethylhexyl, 3,3-dimtheylpentyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylpentyl, 3-ethylpentyl, 2-ethyl
- alkoxy refers to an alkyl group which is attached to another moiety by an oxygen atom.
- alkoxy groups include, without being limited to, methoxy, isopropoxy, ethoxy, tert-butoxy. Alkoxy groups may be optionally substituted with one or more substituents.
- cycloalkyl refers to a saturated cyclic alkyl radical having from 3 to 10 carbon atoms.
- Representative cycloalkyls include cyclopropyl, 1-methylcyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, and cyclodecyl.
- Cycloalkyl groups can be optionally substituted with one or more substituents.
- halogen refers to -F, -Cl, -Br or -I.
- heteroaryl refers to a monocyclic or polycyclic heteroaromatic ring comprising carbon atom ring members and one or more heteroatom ring members (such as, for example, oxygen, sulfur or nitrogen). Typically, a heteroaryl group has from 1 to about 5 heteroatom ring members and from 1 to about 14 carbon atom ring members.
- heteroaryl groups include, without being limited to, pyridyl, 1-oxo-pyridyl, furanyl, benzo[1,3]dioxolyl, benzo[1,4]dioxinyl, thienyl, pyrrolyl, oxazolyl, imidazolyl, thiazolyl, isoxazolyl, quinolinyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, triazolyl, thiadiazolyl, isoquinolinyl, indazolyl, benzoxazolyl, benzofuryl, indolizinyl, imidazopyridyl, tetrazolyl, benzimidazolyl, benzothiazolyl, benzothiadiazolyl, benzoxadiazolyl, indolyl, tetrahydroind
- a heteroatom may be substituted with a protecting group known to those of ordinary skill in the art, for example, the hydrogen on a nitrogen may be substituted with a tert-butoxycarbonyl group.
- Heteroaryl groups may be optionally substituted with one or more substituents.
- nitrogen or sulfur heteroatom ring members may be oxidized.
- the heteroaromatic ring is selected from 5-8 membered monocyclic heteroaryl rings. The point of attachment of a heteroaromatic or heteroaryl ring to another group may be at either a carbon atom or a heteroatom of the heteroaromatic or heteroaryl rings.
- heterocycle refers collectively to heterocycloalkyl groups and heteroaryl groups.
- heterocycloalkyl refers to a monocyclic or polycyclic group having at least one heteroatom selected from O, N or S, and which has 2-11 carbon atoms, which may be saturated or unsaturated, but is not aromatic.
- heterocycloalkyl groups include, without being limited to, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 4-piperidonyl, pyrrolidinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydropyrindinyl, tetrahydropyrimidinyl, tetrahydrothiopyranyl sulfone, tetrahydrothiopyranyl sulfoxide, morpholinyl, thiomorpholinyl, thiomorpholinyl sulfoxide, thiomorpholinyl sulfone, 1,3-dioxolane, tetrahydrofuranyl, dihydrofuranyl-2-one, thi
- monocyclic heterocycloalkyl groups have 3 to 7 members.
- Preferred 3 to 7 membered monocyclic heterocycloalkyl groups are those having 5 or 6 ring atoms.
- a heteroatom may be substituted with a protecting group known to those of ordinary skill in the art, for example, the hydrogen on a nitrogen may be substituted with a tert-butoxycarbonyl group.
- heterocycloalkyl groups may be optionally substituted with one or more substituents.
- the point of attachment of a heterocyclic ring to another group may be at either a carbon atom or a heteroatom of a heterocyclic ring. Only stable isomers of such substituted heterocyclic groups are contemplated in this definition.
- substituted means that a hydrogen radical on a compound or group is replaced with any desired group that is substantially stable to reaction conditions in an unprotected form or when protected using a protecting group.
- substituents include, without being limited to, halogen (chloro, iodo, bromo, or fluoro); alkyl; alkenyl; alkynyl; hydroxy; alkoxy; nitro; thiol; thioether; imine; cyano; amido; phosphonato; phosphine; carboxyl; thiocarbonyl; sulfonyl; sulfonamide; ketone; aldehyde; ester; oxygen (-O); haloalkyl (e.g., trifluoromethyl); cycloalkyl, which may be monocyclic or fused or non-fused polycyclic (e.g., cyclopropyl,
- substituents may optionally be further substituted with a substituent selected from such groups.
- substituted refers to a substituent selected from the group consisting of an alkyl, an alkenyl, an alkynyl, an cycloalkyl, an cycloalkenyl, a heterocycloalkyl, an aryl, a heteroaryl, an arylalkyl, a heteroarylalkyl, a haloalkyl, -C(O)NR 11 R 12 , -NR 13 C(O)R 14 , a halo, -OR 13 , cyano, nitro, a haloalkoxy, -C(O)R 13 , -NR 11 R 12 , -SR 13 , -C(O)OR 13 , -OC(O)R 13 , -NR 13 C(O)NR 11 R 12 , -OC(O)
- solubilizing group refers to any group which can be substantially ionized and that enables the compound to be soluble in a desired solvent, such as, for example, water or water-containing solvent ("water-solubilizing group"). Furthermore, the solubilizing group can be one that increases the compound or complex's lipophilicity.
- the solubilizing group is selected from alkyl group substituted with one or more heteroatoms such as N, O, S, each optionally substituted with alkyl group substituted independently with alkoxy, amino, alkylamino, dialkylamino, carboxyl, cyano, or substituted with cycloheteroalkyl or heteroaryl, or a phosphate, or a sulfate, or a carboxylic acid.
- the solubilizing group is one of the following:
- the solubilizing group is one of the following:
- the solubilizing group is a saturated cyclic amino group (including, without being limited to, piperidinyl, piperazinyl and pyrrolidinyl) which may be substituted by a group consisting of alkyl, alkoxycarbonyl, halogen, haloalkyl, hydroxyalkyl, amino, monoalkylamino, dialkylamino, carbamoyl, monoalkylcarbamoyl and dialkylcarbamoyl (including, without being limited to, methyl-piperidinyl, methyl-piperazinyl and methyl-pyrrolidinyl).
- the solubilizing group is structure c) shown above, wherein the wavy line corresponds to the point of attachment to the core structure of the 2-aminoarylthiazole derivative disclosed for example of formula (I) or (II).
- pharmaceutically acceptable salt refers to a salt of a free acid or a free base which is not biologically undesirable and is generally prepared by reacting the free base with a suitable organic or inorganic acid or by reacting the free acid with a suitable organic or inorganic base.
- Suitable acid addition salts are formed from acids that form non-toxic salts.
- Examples include the acetate, adipate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulphate/sulphate, borate, camsylate, citrate, cyclamate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulphate, naphthylate, napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate/hydrogen, phosphate/dihydrogen, phosphate, pyroglutamate, saccharate, stearate, succinate, tannate, tartrate, to
- Suitable base salts are formed from bases that form non-toxic salts. Examples include the aluminum, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine, 2-(diethylamino)ethanol, ethanolamine, morpholine, 4-(2-hydroxyethyl)morpholine and zinc salts. Hemi salts of acids and bases may also be formed, e.g., hemi sulphate and hemi calcium salts.
- pharmaceutically acceptable salts are pharmaceutically acceptable acid addition salts, for example with inorganic acids, such as hydrochloric acid, sulfuric acid or a phosphoric acid, or with suitable organic carboxylic or sulfonic acids, for example aliphatic mono- or di-carboxylic acids, such as trifluoroacetic acid, acetic acid, propionic acid, glycolic acid, succinic acid, maleic acid, fumaric acid, hydroxymaleic acid, malic acid, tartaric acid, citric acid or oxalic acid, or amino acids such as arginine or lysine, aromatic carboxylic acids, such as benzoic acid, 2-phenoxy-benzoic acid, 2-acetoxy-benzoic acid, salicylic acid, 4-aminosalicylic acid, aromatic-aliphatic carboxylic acids, such as mandelic acid or cinnamic acid, heteroaromatic carboxylic acids, such as nicotinic acid or isonicotinic acid, aliphatic mono
- the pharmaceutically acceptable salt of the 2-aminoarylthiazole derivative of the invention is mesilate.
- mesilate is used herein to refer to a salt of methanesulfonic acid with a named pharmaceutical substance (such as 2-aminoarylthiazole derivatives of formula (I) or (II)).
- a named pharmaceutical substance such as 2-aminoarylthiazole derivatives of formula (I) or (II)
- Use of mesilate rather than mesylate is in compliance with the INNM (International nonproprietary names modified) issued by WHO (e.g., World Health Organization (February 2006). International Nonproprietary Names Modified. INN Working Document 05.167/3. WHO ).
- pharmaceutically acceptable solvate refers to a molecular complex comprising the 2-aminoarylthiazole derivative disclosed and stoichiometric or sub-stoichiometric amounts of one or more pharmaceutically acceptable solvent molecules such as ethanol.
- solvent molecules such as ethanol.
- 'hydrate' refers to when said solvent is water.
- the 2-aminoarylthiazole derivative of the invention or a pharmaceutically acceptable salt or solvate thereof is masitinib or a pharmaceutically acceptable salt or solvate thereof.
- masitinib was first described in US 7,423,055 and EP 1 525 200 B1 .
- the 2-aminoarylthiazole derivative of the invention or a pharmaceutically acceptable salt or solvate thereof is masitinib mesilate.
- the pharmaceutically acceptable salt of masitinib as described above is masitinib mesilate.
- the pharmaceutically acceptable salt of masitinib is the methanesulfonic acid salt of masitinib.
- masitinib mesilate refers to the orally bioavailable mesilate salt of masitinib - CAS 1048007-93-7 (MsOH); C28H30N6OS.CH3SO3H; MW 594.76:
- the 2-aminoarylthiazole derivative as described above in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, is for administration at a therapeutically effective dose.
- the 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof is for administration at a dose ranging from about 1 to about 12 mg/kg/day (mg per kilo body weight per day). In one embodiment, the 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, is for administration at a dose ranging from about 1.5 to about 7.5 mg/kg/day.
- the 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof is for administration at a dose ranging from about 3 to about 12 mg/kg/day, preferably from about 3 to about 6 mg/kg/day.
- the 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof is for administration at a dose of about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 mg/kg/day. In one embodiment, the 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, is for administration at a dose of about 1.5, 3, 4.5, 6, 7.5, 9, 10.5, or 12 mg/kg/day.
- the 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof is for administration at a dose of about 3, 4.5, or 6 mg/kg/day, preferably at a dose of about 6 mg/kg/day.
- the 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof can be dose escalated by increments of about 1.5 mg/kg/day to reach a maximum of about 7.5 mg/kg/day, more preferably of about 4.5 or about 6 mg/kg/day.
- Each dose escalation is subjected to toxicity controls with an absence of any toxicity events permitting dose escalation to occur.
- the dose escalation of the 2-aminoarylthiazole derivative, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof occurs at any time-point after at least 4 weeks after the administration of the initial dose and prior to 26 weeks after the administration of the initial dose; for example at 4 weeks, 8 weeks, 12 weeks, 16 weeks, 20 weeks, or 24 weeks after the administration of the initial dose, preferably at 12 weeks after the administration of the initial dose.
- Each dose escalation is subjected to toxicity controls, including for example: previous 4-week treatment period at a constant dose of study treatment and no suspected severe adverse event was reported and no suspected adverse event led to treatment interruption and no suspected adverse event is ongoing at the time of the dose increase, regardless of its severity.
- the 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof is for administration at an initial dose of about 3 mg/kg/day during 6 weeks, then at a dose of about 4.5 mg/kg/day thereafter. In one embodiment, the 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, is for administration at an initial dose of about 4.5 mg/kg/day during 6 weeks, then at a dose of about 6 mg/kg/day thereafter.
- the 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof is for administration at an initial dose of about 3 mg/kg/day during 12 weeks, then at a dose of about 4.5 mg/kg/day thereafter. In one embodiment, the 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, is for administration at an initial dose of about 4.5 mg/kg/day during 12 weeks, then at a dose of about 6 mg/kg/day thereafter.
- the 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof is for administration at an initial dose of about 3 mg/kg/day during at least 4 weeks, then at a dose of about 4.5 mg/kg/day during at least 4 weeks, and at a dose of about 6 mg/kg/day thereafter, with each dose escalation being subjected to toxicity controls.
- any dose indicated herein refers to the amount of active ingredient as such, not to its pharmaceutically acceptable salt or solvate form.
- compositional variations of a pharmaceutically acceptable salt or solvate of the 2-aminoarylthiazole derivative disclosed, in particular masitinib will not impact the dose to be administered.
- the 2-aminoarylthiazole derivative disclosed in particular masitinib, or a pharmaceutically acceptable salt or solvate as described above, is adapted for an administration at a dose as described above.
- the 2-aminoarylthiazole derivative as described above may be administered orally, intravenously, parenterally, topically, by inhalation in particular by inhalation spray, rectally, nasally, or buccally.
- the 2-aminoarylthiazole derivative as described above, preferably masitinib, or a pharmaceutically acceptable salt or solvate thereof is for oral administration.
- the 2-aminoarylthiazole derivative as described above, preferably masitinib, or a pharmaceutically acceptable salt or solvate thereof is for administration at least once a day, preferably twice a day. In one embodiment, the 2-aminoarylthiazole derivative as described above, preferably masitinib, or a pharmaceutically acceptable salt or solvate thereof, is for prolonged administration, such as for example, for at least 1, 2, 3, 6, 9, or 12 months.
- the 2-aminoarylthiazole derivative as described above preferably masitinib, or a pharmaceutically acceptable salt or solvate thereof, is adapted or is in a form adapted for oral administration.
- forms adapted for oral administration include, without being limited to, liquid, paste or solid compositions, and more particularly tablets, pills, capsules, liquids, gels, syrups, slurries, and suspensions.
- the 2-aminoarylthiazole derivative as described above preferably masitinib, or a pharmaceutically acceptable salt or solvate thereof, is for administration as tablets, preferably as 100 mg or 200 mg tablets.
- the 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, is for administration with at least one further pharmaceutically active agent.
- the 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, may be administered simultaneously, separately or sequentially with said at least one further pharmaceutically active agent.
- the 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, is to be administered in combination with said at least one further pharmaceutically active agent, such as in a combined preparation, pharmaceutical composition or medicament.
- the 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, and the at least one further pharmaceutically active agent are to be administered separately.
- said at least one further pharmaceutically active agent is selected from chemotherapeutic agents and corticoids.
- the 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, is for administration with a chemotherapeutic agent.
- said chemotherapeutic agent is docetaxel or cabazitaxel.
- the 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, is for administration with docetaxel.
- the 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof is for administration with at least one corticosteroid.
- corticosteroids include, but are not limited to, prednisone.
- the 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof is for administration with prednisone.
- the 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof is for administration with a chemotherapeutic agent, such as docetaxel, and at least one corticosteroid, such as, for example, prednisone.
- a chemotherapeutic agent such as docetaxel
- at least one corticosteroid such as, for example, prednisone.
- the 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof is for administration with docetaxel and prednisone.
- Futher disclosed is a method for treating prostate cancer (preferably CRPC, more preferably mCRPC, and in particular early mCRPC associated with alkaline phosphatase (ALP) levels at baseline equal to or lower than 250 IU/L, and/or with a Halabi prognosis score (H) at baseline equal to or lower than 45) in a subject in need thereof as defined above, comprising administering to the subject a 2-aminoarylthiazole derivative, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof as described above.
- ALP alkaline phosphatase
- H Halabi prognosis score
- the method is for treating early mCRPC as defined herein.
- the method comprises administering a therapeutically effective dose of 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof.
- the method comprises administering at least one further pharmaceutically active agent as described herein.
- said at least one further pharmaceutically active agent is selected from chemotherapeutic agents and corticoids.
- a pharmaceutical composition for treating or for use in the treatment of prostate cancer preferably CRPC, more preferably mCRPC, and in particular early mCRPC associated with alkaline phosphatase (ALP) levels at baseline equal to or lower than 250 IU/L, and/or with a Halabi prognosis score (H) at baseline equal to or lower than 45
- said pharmaceutical composition comprising a 2-aminoarylthiazole derivative, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof as described above and optionally at least one pharmaceutically acceptable excipient.
- the pharmaceutical composition is for treating or for use in the treatment of early mCRPC as defined herein.
- the pharmaceutical composition is for administration with at least one further pharmaceutically active agent as described herein.
- the pharmaceutical composition may be administered simultaneously, separately or sequentially with said at least one further pharmaceutically active agent.
- said at least one further pharmaceutically active agent is selected from chemotherapeutic agents and corticoids.
- a 2-aminoarylthiazole derivative in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof as described above, for the manufacture of a medicament for the treatment of prostate cancer (preferably CRPC, more preferably mCRPC, and in particular early mCRPC associated with alkaline phosphatase levels at baseline equal to or lower than 250 IU/L, and/or with a Halabi prognosis score (H) at baseline equal to or lower than 45) in a subject in need thereof as defined above.
- CRPC preferably CRPC, more preferably mCRPC, and in particular early mCRPC associated with alkaline phosphatase levels at baseline equal to or lower than 250 IU/L, and/or with a Halabi prognosis score (H) at baseline equal to or lower than 45
- a 2-aminoarylthiazole derivative in particular masitinib, or a pharmaceutically acceptable salt thereof as described above, for the manufacture of a medicament for the treatment of early mCRPC as defined herein.
- the medicament is for administration with at least one further pharmaceutically active agent as described herein.
- the medicament may be administered simultaneously, separately or sequentially with said at least one further pharmaceutically active agent.
- said at least one further pharmaceutically active agent is selected from chemotherapeutic agents and corticoids.
- phase 3 study was conducted to assess the efficacy and safety of masitinib in combination with docetaxel as compared to placebo in combination with docetaxel in first line metastatic castrate-resistant prostate cancer (mCRPC).
- the objective of the study was to assess the efficacy and safety of masitinib in combination with docetaxel as compared to docetaxel in combination with placebo in first line metastatic castrate-resistant prostate cancer (mCRPC). Efficacy was assessed based on the progression-free survival (PFS), measured in months.
- PFS progression-free survival
- the patients recruited in the study consist of adult males suffering from prostate cancer who progressed to develop castration-resistant prostate cancer (CRPC) after castration treatment (reduction of androgens (e.g., testosterone, dihydrotestosterone (DHT)) by chemical or surgical means). These patients are considered to be patients in the first line metastatic castration-resistant prostate cancer (mCRPC).
- CRPC castration-resistant prostate cancer
- IWRS Interactive Web Response System
- Inclusion criteria were: - Patient aged ⁇ 18 years old, with histologically or cytologically confirmed metastatic castrate-resistant prostate cancer (medical or surgical castration: androgens deprivation by GnRH agonist or antagonist or patient with surgical castration; hormonal castration confirmed biologically (testosterone ⁇ 0.5ng/mL) with one of the following criteria: ⁇ If surgical castration is done than there is no requirement to perform testosterone test.
- the Halabi prognosis score is based on the method described by Halabi et al. (J Clin Oncol. 2003 Apr 1;21(7):1232-7 ) and is used as an estimate of patient survival.
- the mathematic formula is based on the measurement of visceral disease (yes or no, the value of this parameter being equal to 1 if the subject is affected with visceral disease, and 0 if he is not), initial Gleason score (the value being equal to 1 if the Gleason score measured for the subject ranges from 8 to 10, and 0 if the Gleason score is inferior to 8), ECOG (Eastern Cooperative Oncology Group) performance status (ranging from 0 to 2), prostate specific antigen (PSA) levels (PSA, measured in ng/mL), lactic acid dehydrogenase (LDH) levels (LDH, measured in IU/L), alkaline phosphatase (ALP) levels (ALP or AP, measured in
- Halabi prognosis score was calculated using the following procedure for a subject having an ECOG performance status of 0 or 1:
- masitinib for treating mCRPC was assessed based on the progression-free survival (expressed by the median progression-free survival measured in months (“Median”), accompanied by the related 95% confidence interval (“95% CI”) and p-value), and on two parameters measured in the subject population.
- a hazard ratio (HR) is measured, corresponding to the probability of death when treated with masitinib (+ docetaxel + prednisone) over the probability of death when treated with placebo (+ docetaxel + prednisone).
- HR ⁇ 1 indicates that the probability of death when treated with masitinib is lower than the probability of death when treated with placebo (and is thus indicative of a therapeutic benefit).
- a "Risk benefit” is measured, allowing to assess the effect of masitinib in a specific subgroup, as compared to the mirror subgroup.
- the therapeutic benefit of masitinib is increased in patients presenting both low ALP levels measured at baseline (i.e., ALP levels at baseline equal to or lower than 250 IU/L), and a low Halabi score (H) measured at baseline (i.e., a Halabi prognosis score (H) at baseline equal to or lower than 33).
Description
- The present invention relates to the treatment of prostate cancer, in particular of castrate-resistant prostate cancer (CRPC).
- Prostate cancer is one of the most common cancers in men. There were an estimated 1,414,259 new cases of prostate cancer diagnosed worldwide in 2020, representing 7.3% of the estimated total new cancer cases (Sung H et al. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660). In the United States of America, the incidence rate, based on the 2013-2017 data, was 104.6 new cases per 100,000 men per year (American Cancer Society, 2018 - Data sources: North American Association of Central Cancer Registries (NAACCR), 2020). In Europe, the average incidence rate was estimated in 2018 at 151.2 new cases per 100,000 men, with an average death rate estimated the same year at 32.8 per 100,000 (Hofmarcher, T et al. (2019) Comparator Report on Cancer in Europe 2019 - Disease Burden, Costs and Access to Medicines. IHE Report 2019:7. IHE: Lund, Sweden).
- Prostate cancer is driven by male sex hormones called androgens, including testosterone and dihydrotestosterone (DHT). Hormone therapy, aiming either at decreasing androgen levels or blocking androgen action, can inhibit the growth of prostate cancer. Usually, the first type of hormone therapy administered to treat prostate cancer is the so-called androgen deprivation therapy (ADT), consisting of treatments reducing androgen production by the testicles. ADT thus includes surgical castration (i.e., orchiectomy) and chemical (or medical) castration. Chemical castration may be obtained through the administration of luteinizing hormone-releasing hormone (LHRH) agonists, sometimes called LHRH analogs, or through the administration of LHRH antagonists. Of note, LHRH is also sometimes called gonadotropin-releasing hormone (GnRH) and, accordingly, LHRH agonists (or analogs) are also known as GnRH agonists (or analogs), and LHRH antagonists as GnRH antagonists.
- Most prostate cancers eventually stop responding to androgen deprivation therapy and thus become castrate- (or castration-) resistant. Castrate-resistant prostate cancer (CRPC) is defined by disease progression despite androgen deprivation therapy and may present as either a continuous rise in serum prostate-specific antigen (PSA) levels, the progression of pre-existing disease, and/or the appearance of new metastases (Saad et al. Can Urol Assoc J. 2010 Dec;4(6):380-4). Treatment options then comprise further hormone therapies, such as antiandrogen therapies including androgen receptor blockers and androgen synthesis inhibitors (for example abiraterone), immunotherapy, and chemotherapy, in particular docetaxel or cabazitaxel.
- Of note, androgen deprivation therapy is also currently part of the standard of care for metastatic prostate cancer. Although the majority of patients with metastatic prostate cancer initially respond to castration, either surgical or chemical, almost all patients with metastatic prostate cancer will also eventually develop castration resistance. These patients are then suffering from metastatic castrate- (or castration-) resistant prostate cancer (mCRPC). Treatment options for mCRPC primarily aim at prolonging life and improving quality of life. However, median survival for patients with mCRPC ranges from approximately 15 to 36 months in recent studies, and 5-year survival is only 28% (Crawford et al. Urol Oncol. 2017 May;35S:S1-S13). The reported impact of currently approved treatments for mCRPC remains modest.
-
US2017/0196853 discloses compositions comprising Masitinib for use in the treatment of mCRPC. - Therefore, there is still a need for effective treatment for metastatic castrate-(or castration-) resistant prostate cancer (mCRPC). In particular, it may be helpful to identify the mCRPC patients most likely to benefit from treatment.
- The present invention thus relates to masitinib, or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of metastatic castrate-resistant prostate cancer (mCRPC) in a subject in need thereof, in particular in a subject most likely to benefit from the administration of masitinib, or a pharmaceutically acceptable salt or solvate thereof, such as a subject having alkaline phosphatase levels at baseline equal to or lower than 250 IU/L and/or with a Halabi prognosis score (H) at baseline equal to or lower than 33.
- The present invention relates to masitinib, or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of metastatic castrate-resistant prostate cancer (mCRPC) in a subject in need therefore, wherein said subject suffers from early mCRPC associated (i) with alkaline phosphatase (ALP) levels at baseline equal to or lower than 250 IU/L, or (ii) with a Halabi prognosis score (H) at baseline equal to or lower than 33, or (iii) with ALP levels at baseline equal to or lower than 250 IUAL and with a Halabi prognosis score (H) at baseline equal to or lower than 33, as defined in the appended claims.
- In one embodiment, said subject has ALP levels at baseline equal to or lower than 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L. In one embodiment, said subject has ALP levels at baseline equal to or lower than 200 IU/L. In one embodiment, said subject has ALP levels at baseline equal to or lower than 150 IU/L. In one embodiment, said subject has ALP levels at baseline equal to or lower than 100 IU/L.
- In one embodiment, said subject has a Halabi prognosis score (H) at baseline equal to or lower than 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15. In one embodiment, said subject has a Halabi prognosis score (H) at baseline equal to or lower than 22.
- In one embodiment, said subject received hormone therapy selected from the group consisting of luteinizing hormone-releasing hormone (LHRH) agonists (also known as gonadotropin-releasing hormone (GnRH) agonists), LHRH antagonists (also known as GnRH antagonists), and abiraterone.
- In one embodiment, the pharmaceutically acceptable salt of masitinib is masitinib mesilate.
- In one embodiment, masitinib, or a pharmaceutically acceptable salt or solvate thereof, is for administration at a dose ranging from about 1 to about 12 mg/kg/day (mg per kilo body weight per day), preferably at a dose ranging from about 3 to about 6 mg/kg/day. In one embodiment, masitinib, or a pharmaceutically acceptable salt or solvate thereof, is for administration at a dose of about 6 mg/kg/day.
- In one embodiment, masitinib, or a pharmaceutically acceptable salt or solvate thereof, is for oral administration. In one embodiment, masitinib, or a pharmaceutically acceptable salt or solvate thereof, is for administration in two daily intakes.
- In one embodiment, masitinib, or a pharmaceutically acceptable salt or solvate thereof, is for administration with at least one further pharmaceutically active agent. In one embodiment, said at least one further pharmaceutically active agent is selected from chemotherapeutic agents and corticoids.
- In the present invention, the following terms have the following meanings:
- "About" preceding a figure encompasses plus or minus 10%, or less, of the value of said figure. It is to be understood that the value to which the term "about" refers is itself also specifically, and preferably, disclosed.
- "ALP" refers to alkaline phosphatase. ALP is a membrane-bound glycoprotein which catalyzes the hydrolysis of organic phosphate esters present in the extracellular space. ALP is ubiquitous and can be found in a number of different tissues (such as, for example, placenta, intestine, kidney, bone, and liver) from which it is released in the blood. As used herein, "ALP levels" refer to ALP levels in the blood, in particular in the serum.
- "Baseline" as used herein refers to the time preceding the start of treatment with a 2-aminoarylthiazole derivative, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, as described herein. For example, for a given subject, the ALP levels at baseline are the ALP levels prior to the administration to the subject of a 2-aminoarylthiazole derivative, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, as described herein. Accordingly, for a given subject, the Halabi prognosis score (H) at baseline is the Halabi prognosis score (H) prior to the administration to the subject of a 2-aminoarylthiazole derivative, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, as described herein.
- "Pharmaceutically acceptable excipient" or "pharmaceutically acceptable carrier" refers to an excipient or carrier that does not produce an adverse, allergic or other untoward reaction when administered to a subject. It includes any and all solvents, such as, for example, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents. A pharmaceutically acceptable excipient or carrier refers to a non-toxic solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. For human administration, preparations should meet sterility, pyrogenicity, general safety and purity standards as required by the regulatory offices such as the FDA (U.S. food and drug administration) or EMA (European medicines agency).
- "Subject" refers to a mammal, preferably a human. In one embodiment, the mammal is selected from cats, dogs, cows, pigs, horses, monkeys, apes and humans. In one embodiment, the mammal is selected from cats, dogs and humans. In one embodiment, the subject is a primate. In one embodiment, the subject is a human. In one embodiment, the subject may be a "patient", i.e., a mammal, preferably a human, who/which is awaiting the receipt of, or is receiving medical care or was/is/will be the object of a medical procedure, or is monitored for the development of prostate cancer. In one embodiment, a "subject in need of treatment" is a subject who is awaiting the receipt of, or is receiving medical care, or was/is/will be the object of a medical procedure, or is monitored for the development of prostate cancer, in particular metastatic castrate-resistant prostate cancer (mCRPC).
- "Therapeutically effective amount" or "therapeutically effective dose" refers to the amount or concentration of a 2-aminoarylthiazole derivative as described herein, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, that is aimed at, without causing significant negative or adverse side effects to the subject in need of treatment, bringing about at least one of the following: (1) slowing down or stopping the progression, aggravation, or deterioration of one or more symptom(s) of castrate-resistant prostate cancer (CRPC), in particular mCRPC, and notably prolonging survival of the subject, in particular progression-free survival; (2) bringing about ameliorations of the symptoms of CRPC, in particular mCRPC; (3) reducing the severity or incidence of CRPC, in particular mCRPC; (4) decreasing prostate specific antigen (PSA) levels (e.g., by at least 30% from baseline PSA levels), (5) curing CRPC, in particular mCRPC, (6) increasing quality of life or (7) decreasing pain intensity.
- "Treating" or "Treatment" refers to a therapeutic treatment, to a prophylactic (or preventative) treatment, or to both a therapeutic treatment and a prophylactic (or preventative) treatment, wherein the object is to prevent, reduce, or slow down (lessen) one or more of the symptom(s) or manifestation(s) of castrate-resistant prostate cancer (CRPC), in particular of mCRPC. In one embodiment, a subject is successfully "treated" for CRPC, in particular mCRPC, if, after receiving a therapeutic amount of a 2-aminoarylthiazole derivative as described herein, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, the subject shows observable and/or measurable reduction in the number or percent of cancer cells or metastatic cells; and/or if the subject shows relief to some extent of one or more of the symptoms associated with CRPC, in particular of mCRPC; reduced PSA levels; reduced pain; reduced morbidity and mortality; and/or improvement in quality of life issues. In one embodiment, a subject is successfully "treated" for CRPC, in particular mCRPC, if, after receiving a therapeutic amount of a 2-aminoarylthiazole derivative as described herein, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, the subject benefits from an extended survival, in particular of an extended progression-free survival. The above parameters for assessing successful treatment and improvement in the disease are readily measurable by routine procedures familiar to a physician.
- The present invention relates to a 2-aminoarylthiazole derivative as described herein, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of prostate cancer in a subject in need thereof as defined hereinafter.
- The prostate cancer is metastatic prostate cancer, in particular metastatic castrate-resistant prostate cancer (mCRPC).
- According to one embodiment, the subject in need of treatment has alkaline phosphatase (ALP) levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L. Thus, according to one embodiment, prior to treatment with a 2-aminoarylthiazole derivative as described herein, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, the subject has ALP levels equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L.
- Methods to measure ALP levels are well-known to one skilled in the art and include, for example, the alkaline phosphatase isoenzyme blood test. ALP levels are expressed in IU/L (international units per liter) or in microkatals per liter (µkat/L). The normal range of ALP levels in human healthy adults is generally considered to be about 44 to about 147 IU/L. ALP levels are often elevated in subjects suffering from prostate cancer (including CRPC), in particular in subjects suffering from metastatic prostate cancer (including mCRPC). ALP levels can thus reach up to about 1000 - 3000 IU/L in human subjects suffering from metastatic prostate cancer (including mCRPC).
- In one embodiment, the subject in need of treatment has ALP levels at baseline equal to or lower than 250 IU/L. In one embodiment, the subject in need of treatment has ALP levels at baseline equal to or lower than 200 IU/L. In one embodiment, the subject in need of treatment has ALP levels at baseline equal to or lower than 150 IU/L. In one embodiment, the subject in need of treatment has ALP levels at baseline equal to or lower than 100 IU/L.
- According to one embodiment, the subject in need of treatment has a Halabi prognosis score (H) at baseline equal to or lower than 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15. Thus, according to one embodiment, prior to treatment with a 2-aminoarylthiazole derivative as described herein, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, the subject has a Halabi prognosis score (H) equal to or lower than 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15.
- As used herein, the so-called Halabi prognosis score (H) is based on the method described by Halabi et al. (J Clin Oncol. 2003 Apr 1;21(7) 1232-7).
- More specifically, the Halabi prognosis score (H) as defined herein is obtained with a mathematic formula used to model and estimate patient survival, which is based on the measurement of visceral disease (yes or no, the value of this parameter being equal to 1 if the subject is affected with visceral disease, and 0 if he is not), initial Gleason score (the value being equal to 1 if the Gleason score measured for the subject ranges from 8 to 10, and 0 if the Gleason score is inferior to 8), ECOG (Eastern Cooperative Oncology Group) performance status (ranging from 0 to 2), prostate specific antigen (PSA) levels (PSA, measured in ng/mL), lactic acid dehydrogenase (LDH) levels (LDH, measured in IU/L), alkaline phosphatase (ALP) levels (ALP or AP, measured in IU/L) and hemoglobin (HB, measured in g/dL).
-
- In the mathematic formula hereinabove, ECOG is for Eastern Cooperative Oncology Group status and corresponds to a scale published in 1982 (Oken et al., Am J Clin Oncol. 1982;5:649-655) and describing a patient's level of functioning in terms of their ability to care for themself, daily activity, and physical ability (walking, working, etc.). The ECOG performance status comprises 6 grades, from 0 (fully active, able to carry on all pre-disease performance without restriction) to 5 (dead). Grade 1 corresponds to a patient restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; grade 2 corresponds to a patient ambulatory and capable of all selfcare but unable to carry out any work activities, up and about more than 50% of waking hours; grade 3 corresponds to a patient capable of only limited selfcare, confined to bed or chair more than 50% of waking hours; and grade 4 corresponds to a completely disabled patient, who cannot carry on any selfcare, totally confined to bed or chair. In the present invention, the ECOG performance status of the subject ranges from 0 to 2.
-
- The Gleason score is a prognostic score for prostate cancer patients, obtained from prostate biopsy samples based on the microscopic appearance. The score ranges from 2 to 10, with higher numbers indicating greater risks and higher mortality. For measuring the score, two patterns are measured, the first one based on the dominant or most common cell morphology (scored 1-5) and the second one based on the non-dominant cell pattern (also scored 1-5). The two patterns are thus combined to obtain a score ranging from 2 to 10. Gleason's patterns are the following: 1 - small, uniform glands, 2 - more stroma between glands, 3 - distinctly infiltrative margins, 4 - irregular masses of neoplastic glands, and 5 - only occasional gland formation.
- Visceral disease is a clinical manifestation of metastatic CRPC, corresponding to the presence of metastasis, predominantly in the lung and liver.
- Methods for measuring lactic acid dehydrogenase (LDH) levels, alkaline phosphatase (ALP or AP) levels, prostate specific antigen (PSA) levels and hemoglobin (HB) levels are well-known to the skilled artisan and commonly implemented in clinical laboratories.
- In one embodiment, the subject in need of treatment has a Halabi prognosis score (H) at baseline equal to or lower than 33. In one embodiment, the subject in need of treatment has a Halabi prognosis score (H) at baseline equal to or lower than 27. In one embodiment, the subject in need of treatment has a Halabi prognosis score (H) at baseline equal to or lower than 22. In one embodiment, the subject in need of treatment has a Halabi prognosis score (H) at baseline equal to or lower than 21. In one embodiment, the subject in need of treatment has a Halabi prognosis score (H) at baseline equal to or lower than 19. In one embodiment, the subject in need of treatment has a Halabi prognosis score (H) at baseline equal to or lower than 18. In one embodiment, the subject in need of treatment has a Halabi prognosis score (H) at baseline equal to or lower than 17. In one embodiment, the subject in need of treatment has a Halabi prognosis score (H) at baseline equal to or lower than 16. In one embodiment, the subject in need of treatment has a Halabi prognosis score (H) at baseline equal to or lower than 15.
- According to one embodiment, the subject in need of treatment was previously treated by castration treatment, corresponding to the reduction of available androgen, testosterone or dihydrotestosterone (DHT), by chemical or surgical means.
- According to one embodiment, the subj ect in need of treatment received hormone therapy selected from the group consisting of luteinizing hormone-releasing hormone (LHRH) agonists (also known as gonadotropin-releasing hormone (GnRH) agonists), LHRH antagonists (also known as GnRH antagonists), and abiraterone. Thus, according to one embodiment, prior to treatment with a 2-aminoarylthiazole derivative as described herein, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, the subject received hormone therapy selected from the group consisting of LHRH agonists (also known as GnRH agonists), LHRH antagonists (also known as GnRH antagonists), and abiraterone. In one embodiment, the subject in need of treatment previously received LHRH agonists (also known as GnRH agonists). Examples of LHRH agonists include, but are not limited to, leuprolide, goserelin, triptorelin and histrelin. In one embodiment, the subject in need of treatment previously received LHRH antagonists (also known as GnRH antagonists). Examples of LHRH antagonists include, but are not limited to, degarelix and relugolix. In one embodiment, the subject in need of treatment previously received abiraterone. In one embodiment, the subject was previously treated by surgical castration.
- Also disclosed is that the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15.
- Also disclosed is that the subject in need of treatment has ALP levels at baseline equal to or lower than 250 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15. In one embodiment, the subject in need of treatment has ALP levels at baseline equal to or lower than 200 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15. Also disclosed is that the subject in need of treatment has ALP levels at baseline equal to or lower than 150 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15. In one embodiment, the subject in need of treatment has ALP levels at baseline equal to or lower than 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15.
- In one embodiment, the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 33. In one embodiment, the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 27. In one embodiment, the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 22. In one embodiment, the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 21. In one embodiment, the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 20. In one embodiment, the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 19. In one embodiment, the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 18. In one embodiment, the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 17. In one embodiment, the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 16. In one embodiment, the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 15.
- According to one embodiment, the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and received hormone therapy selected from the group consisting of luteinizing hormone-releasing hormone (LHRH) agonists (also known as gonadotropin-releasing hormone (GnRH) agonists), LHRH antagonists (also known as GnRH antagonists), and abiraterone.
- In one embodiment, the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 200, 150, or 100 IU/L, and received hormone therapy selected from the group consisting of LHRH agonists (also known as GnRH agonists), LHRH antagonists (also known as GnRH antagonists), and abiraterone.
- Also disclosed is that the subject in need of treatment has a Halabi prognosis score (H) at baseline equal to or lower than 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15, and received hormone therapy selected from the group consisting of LHRH agonists (also known as GnRH agonists), LHRH antagonists (also known as GnRH antagonists), and abiraterone.
- In one embodiment, the subject in need of treatment has a Halabi prognosis score (H) at baseline equal to or lower than 33, 27, 22, 21, 20, 19, 18, 17, 16, or 15, and received hormone therapy selected from the group consisting of LHRH agonists (also known as GnRH agonists), LHRH antagonists (also known as GnRH antagonists), and abiraterone.
- Also disclosed is that the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L; and a Halabi prognosis score (H) at baseline equal to or lower than 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15; and received hormone therapy selected from the group consisting of LHRH agonists (also known as GnRH agonists), LHRH antagonists (also known as GnRH antagonists), and abiraterone.
- Also disclosed is that the subject in need of treatment has ALP levels at baseline equal to or lower than 250 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15; and received hormone therapy selected from the group consisting of LHRH agonists (also known as GnRH agonists), LHRH antagonists (also known as GnRH antagonists), and abiraterone. Also disclosed is that the subject in need of treatment has ALP levels at baseline equal to or lower than 200 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15; and received hormone therapy selected from the group consisting of LHRH agonists (also known as GnRH agonists), LHRH antagonists (also known as GnRH antagonists), and abiraterone. Also disclosed is that the subject in need of treatment has ALP levels at baseline equal to or lower than 150 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15; and received hormone therapy selected from the group consisting of LHRH agonists (also known as GnRH agonists), LHRH antagonists (also known as GnRH antagonists), and abiraterone. Also disclosed is that the subject in need of treatment has ALP levels at baseline equal to or lower than 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15; and received hormone therapy selected from the group consisting of LHRH agonists (also known as GnRH agonists), LHRH antagonists (also known as GnRH antagonists), and abiraterone.
- In one embodiment, the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 33; and received hormone therapy selected from the group consisting of LHRH agonists (also known as GnRH agonists), LHRH antagonists (also known as GnRH antagonists), and abiraterone.
- In one embodiment, the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 27; and received hormone therapy selected from the group consisting of LHRH agonists (also known as GnRH agonists), LHRH antagonists (also known as GnRH antagonists), and abiraterone.
- In one embodiment, the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 22; and received hormone therapy selected from the group consisting of LHRH agonists (also known as GnRH agonists), LHRH antagonists (also known as GnRH antagonists), and abiraterone.
- In one embodiment, the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 21; and received hormone therapy selected from the group consisting of LHRH agonists (also known as GnRH) agonists, LHRH antagonists (also known as GnRH antagonists), and abiraterone.
- In one embodiment, the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 20; and received hormone therapy selected from the group consisting of LHRH agonists (also known as GnRH agonists), LHRH antagonists (also known as GnRH antagonists), and abiraterone.
- In one embodiment, the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 19; and received hormone therapy selected from the group consisting of LHRH agonists (also known as GnRH agonists), LHRH antagonists (also known as GnRH antagonists), and abiraterone.
- In one embodiment, the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 18; and received hormone therapy selected from the group consisting of LHRH agonists (also known as GnRH agonists), LHRH antagonists (also known as GnRH antagonists), and abiraterone.
- In one embodiment, the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 17; and received hormone therapy selected from the group consisting of LHRH agonists (also known as GnRH agonists), LHRH antagonists (also known as GnRH antagonists), and abiraterone.
- In one embodiment, the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 16; and received hormone therapy selected from the group consisting of LHRH agonists (also known as GnRH agonists), LHRH antagonists (also known as GnRH antagonists), and abiraterone.
- In one embodiment, the subject in need of treatment has ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 15; and received hormone therapy selected from the group consisting of LHRH agonists (also known as GnRH agonists), LHRH antagonists (also known as GnRH antagonists), and abiraterone.
- Also disclosed is that the subject in need of treatment suffers from early metastatic castrate-resistant prostate cancer (mCRPC) associated with ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and/or with a Halabi prognosis score (H) at baseline equal to or lower than 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15. Also disclosed is that the subject in need of treatment suffers from early mCRPC associated (i) with ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, or (ii) with a Halabi prognosis score (H) at baseline equal to or lower than 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15, or (iii) with ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L and with a Halabi prognosis score (H) at baseline equal to or lower than 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15,
- Also disclosed is that the subject in need of treatment suffers from mCRPC associated with ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L or with a Halabi prognosis score (H) at baseline equal to or lower than 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15.
- Also disclosed is that the subject in need of treatment suffers from early mCRPC associated with ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L and with a Halabi prognosis score (H) at baseline equal to or lower than 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15.
- Also disclosed is that the subject in need of treatment suffers from early mCRPC associated with ALP levels at baseline equal to or lower than 250 IU/L and/or with a Halabi prognosis score (H) at baseline equal to or lower than 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15. Also disclosed is that the subject in need of treatment suffers from early mCRPC associated with ALP levels at baseline equal to or lower than 200 IU/L and/or with a Halabi prognosis score (H) at baseline equal to or lower than 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15. Also disclosed is that the subject in need of treatment suffers from early mCRPC associated with ALP levels at baseline equal to or lower than 150 IU/L and/or with a Halabi prognosis score (H) at baseline equal to or lower than 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15. Also disclosed is that the subject in need of treatment suffers from early mCRPC associated with ALP levels at baseline equal to or lower than 100 IU/L and/or with a Halabi prognosis score (H) at baseline equal to or lower than 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15.
- In one embodiment, the subject in need of treatment suffers from early mCRPC associated with ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 33. In one embodiment, the subject in need of treatment suffers from early mCRPC associated with ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 27. In one embodiment, the subject in need of treatment suffers from early mCRPC associated with ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 22. In one embodiment, the subject in need of treatment suffers from early mCRPC associated with ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) baseline equal to or lower than 21. In one embodiment, the subject in need of treatment suffers from early mCRPC associated with ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 20. In one embodiment, the subject in need of treatment suffers from early mCRPC associated with ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 19. In one embodiment, the subject in need of treatment suffers from early mCRPC associated with ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 18. In one embodiment, the subject in need of treatment suffers from early mCRPC associated with ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 17. In one embodiment, the subject in need of treatment suffers from early mCRPC associated with ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 16. In one embodiment, the subject in need of treatment suffers from early mCRPC associated with ALP levels at baseline equal to or lower than 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L, and a Halabi prognosis score (H) at baseline equal to or lower than 15.
- According to one embodiment, the subject in need of treatment suffers from early mCRPC as defined hereinabove and received (preferably before the initiation of the treatment with a 2-aminoarylthiazole derivative as described herein) hormone therapy selected from the group consisting of luteinizing hormone-releasing hormone (LHRH) agonists (also known as gonadotropin-releasing hormone (GnRH) agonists), LHRH antagonists (also known as GnRH antagonists), and abiraterone.
- In one embodiment, the subject in need of treatment is an adult. According to the present invention, an adult is a subject above the age of 18, 19, 20, or 21 years. In one embodiment, the subject in need of treatment is older than 20, 25, or 30 years. According to one embodiment, the subject in need of treatment is a child. According to the present invention, a child is a subject below the age of 21, 20, 19, or 18 years.
- In one embodiment, the subject in need of treatment has an ECOG performance status of 0 or 1. In another embodiment, the subject in need of treatment has an ECOG performance status of 2.
- In one embodiment, the subject is receiving androgen deprivation therapy selected from the group consisting of luteinizing hormone-releasing hormone (LHRH) agonists (also known as gonadotropin-releasing hormone (GnRH) agonists) and LHRH antagonists (also known as GnRH antagonists).
- As used herein, a 2-aminoarylthiazole derivative refers to a compound characterized by the presence of a thiazolyl group substituted on position 2 (i.e., between the heterocyclic nitrogen and sulfur atoms) by a secondary or tertiary amine, wherein the nitrogen atom of the amine is substituted by at least one aryl group.
- According to one embodiment, the aryl group is substituted by an arylamide group (i.e., NH CO aryl).
-
- R1 and R2 are selected independently from hydrogen, halogen, (C1-C10) alkyl, (C3-C10) cycloalkyl group, trifluoromethyl, alkoxy, cyano, dialkylamino, a solubilizing group, and (C1-C10) alkyl substituted by a solubilizing group;
- m is 0-5;
- n is 0-4;
- R3 is one of the following:
- (i) an aryl group (such as phenyl), the aryl group being optionally substituted by one or more substituents such as halogen, (C1-C10) alkyl group, trifluoromethyl, cyano and alkoxy;
- (ii) a heteroaryl group (such as 2, 3, or 4-pyridyl group), the heteroaryl group being optionally substituted by one or more substituents such as halogen, (C1-C10) alkyl group, trifluoromethyl and alkoxy;
- (iii) a five-membered ring aromatic heterocyclic group (such as, for example, 2-thienyl, 3-thienyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl), the aromatic heterocyclic group being optionally substituted by one or more substituents such as halogen, (C1-C10) alkyl group, trifluoromethyl, and alkoxy.
- Thus, the 2-aminoarylthiazole derivative disclosed or a pharmaceutically acceptable salt or solvate thereof is a 2-aminoarylthiazole derivative of formula (I) or a pharmaceutically acceptable salt or solvate thereof.
-
- R1 is selected independently from hydrogen, halogen, (C1-C10) alkyl, (C3-C10) cycloalkyl group, trifluoromethyl, alkoxy, amino, alkylamino, dialkylamino, a solubilizing group, and (C1-C10) alkyl substituted by a solubilizing group; and
- m is 0-5.
- In one embodiment, R1 of formula (II) is a solubilizing group. In one embodiment, R1 of formula (II) is (C1-C10) alkyl substituted by a solubilizing group.
- In one embodiment, R1 of formula (II) is (C1-C10) alkyl-(C2-C11) heterocycloalkyl-(C1-C10) alkyl-. In one embodiment, R1 of formula (II) is (C1-C4) alkyl-(C2-C11) heterocycloalkyl-(C1-C10) alkyl-, preferably (C1-C2) alkyl-(C2-C11) heterocycloalkyl-(C1-C10) alkyl-. In one embodiment, R1 of formula (II) is (C1-C10) alkyl-(C2-C11) heterocycloalkyl-(C1-C4) alkyl-, preferably (C1-C10) alkyl-(C2-C11) heterocycloalkyl-(C1-C2) alkyl-. In one embodiment, R1 of formula (II) is (C1-C10) alkyl-(C2-C6) heterocycloalkyl-(C1-C10) alkyl-, preferably (C1-C10) alkyl-(C4) heterocycloalkyl-(C1-C10) alkyl-. In one embodiment, R1 of formula (II) is (C1-C4) alkyl-(C2-C6) heterocycloalkyl-(C1-C4) alkyl-, preferably (C1-C2) alkyl-(C4) heterocycloalkyl-(C1-C2) alkyl-. In one embodiment, R1 of formula (II) is (C1-C4) alkyl-piperazinyl-(C1-C4) alkyl-, preferably (C1-C2) alkyl-piperazinyl-(C1-C2) alkyl-. In one embodiment, R1 of formula (II) is methylpiperazinyl-(C1-C2) alkyl-, preferably methylpiperazinyl-methyl-, more preferably 4-methylpiperazinyl-methyl-.
- Thus, the 2-aminoarylthiazole derivative disclosed or a pharmaceutically acceptable salt or solvate thereof is a 2-aminoarylthiazole derivative of formula (II) as described above or a pharmaceutically acceptable salt or solvate thereof.
- As used herein, the term "aryl group" refers to a polyunsaturated, aromatic hydrocarbyl group having a single aromatic ring (i.e., phenyl) or multiple aromatic rings fused together (e.g., naphtyl) or linked covalently, typically containing 5 to 12 atoms; preferably 6 to 10, wherein at least one ring is aromatic. The aromatic ring may optionally include one to two additional rings (either cycloalkyl, heterocyclyl or heteroaryl) fused thereto. Aryl is also intended to include the partially hydrogenated derivatives of the carbocyclic systems enumerated herein. Examples of suitable aryl groups include, without being limited to, phenyl, tolyl, anthracenyl, fluorenyl, indenyl, azulenyl, and naphthyl, as well as benzo-fused carbocyclic moieties such as 5,6,7,8-tetrahydronaphthyl. An aryl group can be unsubstituted or substituted with one or more substituents. In one embodiment, the aryl group is a monocyclic ring, wherein the ring comprises 6 carbon atoms, referred to herein as "(C6) aryl".
- As used herein, the term "alkyl group" refers to a saturated straight chain or branched non-cyclic hydrocarbon having from 1 to 10 carbon atoms, preferably from 1 to 6 carbon atoms. Representative saturated straight chain alkyls include, without being limited to, methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl and n-decyl. Saturated branched alkyls include, without being limited to, isopropyl, sec-butyl, isobutyl, tert-butyl, isopentyl, 2-methylbutyl, 3-methylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2,3-dimethylbutyl, 2,3-dimethylpentyl, 2,4-dimethylpentyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylpentyl, 2,2-dimethylhexyl, 3,3-dimtheylpentyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylpentyl, 3-ethylpentyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, 2-methyl-4-ethylpentyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2-methyl-4-ethylhexyl, 2,2-diethylpentyl, 3,3-diethylhexyl, 2,2-diethylhexyl, 3,3-diethylhexyl. Alkyl groups included in compounds disclosed may be optionally substituted with one or more substituents.
- As used herein, the term "alkoxy" refers to an alkyl group which is attached to another moiety by an oxygen atom. Examples of alkoxy groups include, without being limited to, methoxy, isopropoxy, ethoxy, tert-butoxy. Alkoxy groups may be optionally substituted with one or more substituents.
- As used herein, the term "cycloalkyl" refers to a saturated cyclic alkyl radical having from 3 to 10 carbon atoms. Representative cycloalkyls include cyclopropyl, 1-methylcyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, and cyclodecyl. Cycloalkyl groups can be optionally substituted with one or more substituents.
- As used herein, the term "halogen" refers to -F, -Cl, -Br or -I.
- As used herein, the term "heteroaryl" refers to a monocyclic or polycyclic heteroaromatic ring comprising carbon atom ring members and one or more heteroatom ring members (such as, for example, oxygen, sulfur or nitrogen). Typically, a heteroaryl group has from 1 to about 5 heteroatom ring members and from 1 to about 14 carbon atom ring members. Representative heteroaryl groups include, without being limited to, pyridyl, 1-oxo-pyridyl, furanyl, benzo[1,3]dioxolyl, benzo[1,4]dioxinyl, thienyl, pyrrolyl, oxazolyl, imidazolyl, thiazolyl, isoxazolyl, quinolinyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, triazolyl, thiadiazolyl, isoquinolinyl, indazolyl, benzoxazolyl, benzofuryl, indolizinyl, imidazopyridyl, tetrazolyl, benzimidazolyl, benzothiazolyl, benzothiadiazolyl, benzoxadiazolyl, indolyl, tetrahydroindolyl, azaindolyl, imidazopyridyl, quinazolinyl, purinyl, pyrrolo[2,3]pyrimidinyl, pyrazolo[3,4]pyrimidinyl, imidazo[1,2-a]pyridyl, and benzo(b)thienyl. A heteroatom may be substituted with a protecting group known to those of ordinary skill in the art, for example, the hydrogen on a nitrogen may be substituted with a tert-butoxycarbonyl group. Heteroaryl groups may be optionally substituted with one or more substituents. In addition, nitrogen or sulfur heteroatom ring members may be oxidized. In one embodiment, the heteroaromatic ring is selected from 5-8 membered monocyclic heteroaryl rings. The point of attachment of a heteroaromatic or heteroaryl ring to another group may be at either a carbon atom or a heteroatom of the heteroaromatic or heteroaryl rings.
- As used herein, the term "heterocycle" refers collectively to heterocycloalkyl groups and heteroaryl groups.
- As used herein, the term "heterocycloalkyl" refers to a monocyclic or polycyclic group having at least one heteroatom selected from O, N or S, and which has 2-11 carbon atoms, which may be saturated or unsaturated, but is not aromatic. Examples of heterocycloalkyl groups include, without being limited to, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 4-piperidonyl, pyrrolidinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydropyrindinyl, tetrahydropyrimidinyl, tetrahydrothiopyranyl sulfone, tetrahydrothiopyranyl sulfoxide, morpholinyl, thiomorpholinyl, thiomorpholinyl sulfoxide, thiomorpholinyl sulfone, 1,3-dioxolane, tetrahydrofuranyl, dihydrofuranyl-2-one, tetrahydrothienyl, and tetrahydro-1, 1-dioxothienyl. Typically, monocyclic heterocycloalkyl groups have 3 to 7 members. Preferred 3 to 7 membered monocyclic heterocycloalkyl groups are those having 5 or 6 ring atoms. A heteroatom may be substituted with a protecting group known to those of ordinary skill in the art, for example, the hydrogen on a nitrogen may be substituted with a tert-butoxycarbonyl group. Furthermore, heterocycloalkyl groups may be optionally substituted with one or more substituents. In addition, the point of attachment of a heterocyclic ring to another group may be at either a carbon atom or a heteroatom of a heterocyclic ring. Only stable isomers of such substituted heterocyclic groups are contemplated in this definition.
- As used herein, the term "substituent" or "substituted" means that a hydrogen radical on a compound or group is replaced with any desired group that is substantially stable to reaction conditions in an unprotected form or when protected using a protecting group. Examples of preferred substituents include, without being limited to, halogen (chloro, iodo, bromo, or fluoro); alkyl; alkenyl; alkynyl; hydroxy; alkoxy; nitro; thiol; thioether; imine; cyano; amido; phosphonato; phosphine; carboxyl; thiocarbonyl; sulfonyl; sulfonamide; ketone; aldehyde; ester; oxygen (-O); haloalkyl (e.g., trifluoromethyl); cycloalkyl, which may be monocyclic or fused or non-fused polycyclic (e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), or a heterocycloalkyl, which may be monocyclic or fused or non-fused polycyclic (e.g., pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, or thiazinyl), monocyclic or fused or non-fused polycyclic aryl or heteroaryl (e.g., phenyl, naphthyl, pyrrolyl, indolyl, furanyl, thiophenyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, tetrazolyl, pyrazolyl, pyridyl, quinolinyl, isoquinolinyl, acridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, benzimidazolyl, benzothiophenyl, or benzofuranyl); amino (primary, secondary, or tertiary); CO2CH3; CONH2; OCH2CONH2; NH2; SO2NH2; OCHF2; CF3; OCF3; and such moieties may also be optionally substituted by a fused-ring structure or bridge, for example -OCH2O-. These substituents may optionally be further substituted with a substituent selected from such groups. In certain embodiments, the term "substituent" or the adjective "substituted" refers to a substituent selected from the group consisting of an alkyl, an alkenyl, an alkynyl, an cycloalkyl, an cycloalkenyl, a heterocycloalkyl, an aryl, a heteroaryl, an arylalkyl, a heteroarylalkyl, a haloalkyl, -C(O)NR11R12, -NR13C(O)R14, a halo, -OR13, cyano, nitro, a haloalkoxy, -C(O)R13, -NR11R12, -SR13, -C(O)OR13, -OC(O)R13, -NR13C(O)NR11R12, -OC(O)NR11R12, -NR13C(O)OR14, -S(O)rR13, -NR13S(O)rR14, -OS(O)rR14, S(O)rNR11R12, -O, -S, and -N-R13, wherein r is 1 or 2; R11 and R12, for each occurrence are, independently, H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted arylalkyl, or an optionally substituted heteroarylalkyl; or R11 and R12 taken together with the nitrogen to which they are attached is optionally substituted heterocycloalkyl or optionally substituted heteroaryl; and R13 and R14 for each occurrence are, independently, H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted arylalkyl, or an optionally substituted heteroarylalkyl. In certain embodiments, the term "substituent" or the adjective "substituted" refers to a solubilizing group.
- As used herein, the term "solubilizing group" refers to any group which can be substantially ionized and that enables the compound to be soluble in a desired solvent, such as, for example, water or water-containing solvent ("water-solubilizing group"). Furthermore, the solubilizing group can be one that increases the compound or complex's lipophilicity. In one embodiment, the solubilizing group is selected from alkyl group substituted with one or more heteroatoms such as N, O, S, each optionally substituted with alkyl group substituted independently with alkoxy, amino, alkylamino, dialkylamino, carboxyl, cyano, or substituted with cycloheteroalkyl or heteroaryl, or a phosphate, or a sulfate, or a carboxylic acid. In one embodiment, the solubilizing group is one of the following:
- an alkyl, cycloalkyl, aryl, heteroaryl group comprising either at least one nitrogen or oxygen heteroatom and/or which group is substituted by at least one amino group or oxo group (including, without being limited to, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 4-piperidonyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydropyranyl, morpholinyl, 1,3-dioxolane, tetrahydrofuranyl and dihydrofuranyl-2-one);
- an amino group which may be a saturated cyclic amino group (including, without being limited to, piperidinyl, piperazinyl and pyrrolidinyl) which may be substituted by a group consisting of alkyl, alkoxycarbonyl, halogen, haloalkyl, hydroxyalkyl, amino, monoalkylamino, dialkylamino, carbamoyl, monoalkylcarbamoyl and dialkylcarbamoyl (including, without being limited to, methyl-piperidinyl, methyl-piperazinyl and methyl-pyrrolidinyl);
- one of the structures a) to i) shown below, wherein the wavy line and the arrow line correspond to the point of attachment to the core structure of the 2-aminoarylthiazole derivative disclosed for example of formula (I) or (II):
- In one embodiment, the solubilizing group is one of the following:
- an alkyl, cycloalkyl, aryl, heteroaryl group comprising either at least one nitrogen or oxygen heteroatom or which group is substituted by at least one amino group or oxo group;
- an amino group which may be a saturated cyclic amino group which may be substituted by a group consisting of alkyl, alkoxycarbonyl, halogen, haloalkyl, hydroxyalkyl, amino, monoalkylamino, dialkylamino, carbamoyl, monoalkylcarbamoyl and dialkylcarbamoyl;
- one of the structures a) to i) shown above, wherein the wavy line and the arrow line correspond to the point of attachment to the core structure of the 2-aminoarylthiazole derivative disclosed for example of formula (I) or (II).
- In one embodiment, the solubilizing group is a saturated cyclic amino group (including, without being limited to, piperidinyl, piperazinyl and pyrrolidinyl) which may be substituted by a group consisting of alkyl, alkoxycarbonyl, halogen, haloalkyl, hydroxyalkyl, amino, monoalkylamino, dialkylamino, carbamoyl, monoalkylcarbamoyl and dialkylcarbamoyl (including, without being limited to, methyl-piperidinyl, methyl-piperazinyl and methyl-pyrrolidinyl).
- In one embodiment, the solubilizing group is structure c) shown above, wherein the wavy line corresponds to the point of attachment to the core structure of the 2-aminoarylthiazole derivative disclosed for example of formula (I) or (II).
- As used herein, "pharmaceutically acceptable salt" refers to a salt of a free acid or a free base which is not biologically undesirable and is generally prepared by reacting the free base with a suitable organic or inorganic acid or by reacting the free acid with a suitable organic or inorganic base. Suitable acid addition salts are formed from acids that form non-toxic salts. Examples include the acetate, adipate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulphate/sulphate, borate, camsylate, citrate, cyclamate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulphate, naphthylate, napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate/hydrogen, phosphate/dihydrogen, phosphate, pyroglutamate, saccharate, stearate, succinate, tannate, tartrate, tosylate, trifluoroacetate and xinofoate salts. Suitable base salts are formed from bases that form non-toxic salts. Examples include the aluminum, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine, 2-(diethylamino)ethanol, ethanolamine, morpholine, 4-(2-hydroxyethyl)morpholine and zinc salts. Hemi salts of acids and bases may also be formed, e.g., hemi sulphate and hemi calcium salts.
- In one embodiment, pharmaceutically acceptable salts are pharmaceutically acceptable acid addition salts, for example with inorganic acids, such as hydrochloric acid, sulfuric acid or a phosphoric acid, or with suitable organic carboxylic or sulfonic acids, for example aliphatic mono- or di-carboxylic acids, such as trifluoroacetic acid, acetic acid, propionic acid, glycolic acid, succinic acid, maleic acid, fumaric acid, hydroxymaleic acid, malic acid, tartaric acid, citric acid or oxalic acid, or amino acids such as arginine or lysine, aromatic carboxylic acids, such as benzoic acid, 2-phenoxy-benzoic acid, 2-acetoxy-benzoic acid, salicylic acid, 4-aminosalicylic acid, aromatic-aliphatic carboxylic acids, such as mandelic acid or cinnamic acid, heteroaromatic carboxylic acids, such as nicotinic acid or isonicotinic acid, aliphatic sulfonic acids, such as methane-, ethane- or 2-hydroxyethane-sulfonic, in particular methanesulfonic acid, or aromatic sulfonic acids, for example benzene-, p-toluene- or naphthalene-2-sulfonic acid.
- In one embodiment, the pharmaceutically acceptable salt of the 2-aminoarylthiazole derivative of the invention is mesilate.
- Unless otherwise indicated, the term "mesilate" is used herein to refer to a salt of methanesulfonic acid with a named pharmaceutical substance (such as 2-aminoarylthiazole derivatives of formula (I) or (II)). Use of mesilate rather than mesylate is in compliance with the INNM (International nonproprietary names modified) issued by WHO (e.g., World Health Organization (February 2006). International Nonproprietary Names Modified. INN Working Document 05.167/3. WHO).
- As used herein, "pharmaceutically acceptable solvate" refers to a molecular complex comprising the 2-aminoarylthiazole derivative disclosed and stoichiometric or sub-stoichiometric amounts of one or more pharmaceutically acceptable solvent molecules such as ethanol. The term 'hydrate' refers to when said solvent is water.
- The 2-aminoarylthiazole derivative of the invention or a pharmaceutically acceptable salt or solvate thereof is masitinib or a pharmaceutically acceptable salt or solvate thereof.
- The chemical name for masitinib is 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3ylthiazol-2-ylamino) phenyl]benzamide - CAS number 790299-79-5:
US 7,423,055 andEP 1 525 200 B1 . - In one embodiment, the 2-aminoarylthiazole derivative of the invention or a pharmaceutically acceptable salt or solvate thereof is masitinib mesilate. Thus, in one embodiment, the pharmaceutically acceptable salt of masitinib as described above is masitinib mesilate. As mentioned above, in other words, the pharmaceutically acceptable salt of masitinib is the methanesulfonic acid salt of masitinib.
- A detailed procedure for the synthesis of masitinib mesilate is given in
WO 2008/098949 . -
- According to one embodiment, the 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, is for administration at a therapeutically effective dose.
- In one embodiment, the 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, is for administration at a dose ranging from about 1 to about 12 mg/kg/day (mg per kilo body weight per day). In one embodiment, the 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, is for administration at a dose ranging from about 1.5 to about 7.5 mg/kg/day. In one embodiment, the 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, is for administration at a dose ranging from about 3 to about 12 mg/kg/day, preferably from about 3 to about 6 mg/kg/day.
- In one embodiment, the 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, is for administration at a dose of about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 mg/kg/day. In one embodiment, the 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, is for administration at a dose of about 1.5, 3, 4.5, 6, 7.5, 9, 10.5, or 12 mg/kg/day. In one embodiment, the 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, is for administration at a dose of about 3, 4.5, or 6 mg/kg/day, preferably at a dose of about 6 mg/kg/day.
- In one embodiment, the 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, can be dose escalated by increments of about 1.5 mg/kg/day to reach a maximum of about 7.5 mg/kg/day, more preferably of about 4.5 or about 6 mg/kg/day. Each dose escalation is subjected to toxicity controls with an absence of any toxicity events permitting dose escalation to occur.
- In one embodiment, the dose escalation of the 2-aminoarylthiazole derivative, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, occurs at any time-point after at least 4 weeks after the administration of the initial dose and prior to 26 weeks after the administration of the initial dose; for example at 4 weeks, 8 weeks, 12 weeks, 16 weeks, 20 weeks, or 24 weeks after the administration of the initial dose, preferably at 12 weeks after the administration of the initial dose. Each dose escalation is subjected to toxicity controls, including for example: previous 4-week treatment period at a constant dose of study treatment and no suspected severe adverse event was reported and no suspected adverse event led to treatment interruption and no suspected adverse event is ongoing at the time of the dose increase, regardless of its severity.
- In one embodiment, the 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, is for administration at an initial dose of about 3 mg/kg/day during 6 weeks, then at a dose of about 4.5 mg/kg/day thereafter. In one embodiment, the 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, is for administration at an initial dose of about 4.5 mg/kg/day during 6 weeks, then at a dose of about 6 mg/kg/day thereafter. In one embodiment, the 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, is for administration at an initial dose of about 3 mg/kg/day during 12 weeks, then at a dose of about 4.5 mg/kg/day thereafter. In one embodiment, the 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, is for administration at an initial dose of about 4.5 mg/kg/day during 12 weeks, then at a dose of about 6 mg/kg/day thereafter. In one embodiment, the 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, is for administration at an initial dose of about 3 mg/kg/day during at least 4 weeks, then at a dose of about 4.5 mg/kg/day during at least 4 weeks, and at a dose of about 6 mg/kg/day thereafter, with each dose escalation being subjected to toxicity controls.
- According to one embodiment, any dose indicated herein refers to the amount of active ingredient as such, not to its pharmaceutically acceptable salt or solvate form. Thus, compositional variations of a pharmaceutically acceptable salt or solvate of the 2-aminoarylthiazole derivative disclosed, in particular masitinib, will not impact the dose to be administered.
- According to one embodiment, the 2-aminoarylthiazole derivative disclosed, in particular masitinib, or a pharmaceutically acceptable salt or solvate as described above, is adapted for an administration at a dose as described above.
- According to one embodiment, the 2-aminoarylthiazole derivative as described above, preferably masitinib, or a pharmaceutically acceptable salt or solvate thereof, may be administered orally, intravenously, parenterally, topically, by inhalation in particular by inhalation spray, rectally, nasally, or buccally. In one embodiment, the 2-aminoarylthiazole derivative as described above, preferably masitinib, or a pharmaceutically acceptable salt or solvate thereof, is for oral administration.
- In one embodiment, the 2-aminoarylthiazole derivative as described above, preferably masitinib, or a pharmaceutically acceptable salt or solvate thereof, is for administration at least once a day, preferably twice a day. In one embodiment, the 2-aminoarylthiazole derivative as described above, preferably masitinib, or a pharmaceutically acceptable salt or solvate thereof, is for prolonged administration, such as for example, for at least 1, 2, 3, 6, 9, or 12 months.
- In one embodiment, the 2-aminoarylthiazole derivative as described above, preferably masitinib, or a pharmaceutically acceptable salt or solvate thereof, is adapted or is in a form adapted for oral administration. Examples of forms adapted for oral administration include, without being limited to, liquid, paste or solid compositions, and more particularly tablets, pills, capsules, liquids, gels, syrups, slurries, and suspensions.
- In one embodiment, the 2-aminoarylthiazole derivative as described above, preferably masitinib, or a pharmaceutically acceptable salt or solvate thereof, is for administration as tablets, preferably as 100 mg or 200 mg tablets.
- According to one embodiment, the 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, is for administration with at least one further pharmaceutically active agent.
- The 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, may be administered simultaneously, separately or sequentially with said at least one further pharmaceutically active agent.
- In one embodiment, the 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, is to be administered in combination with said at least one further pharmaceutically active agent, such as in a combined preparation, pharmaceutical composition or medicament.
- In one embodiment, the 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, and the at least one further pharmaceutically active agent are to be administered separately.
- In one embodiment, said at least one further pharmaceutically active agent is selected from chemotherapeutic agents and corticoids.
- In one embodiment, the 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, is for administration with a chemotherapeutic agent. In one embodiment, said chemotherapeutic agent is docetaxel or cabazitaxel.
- In one embodiment, the 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, is for administration with docetaxel.
- In one embodiment, the 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, is for administration with at least one corticosteroid. Examples of corticosteroids include, but are not limited to, prednisone. In one embodiment, the 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, is for administration with prednisone.
- In one embodiment, the 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, is for administration with a chemotherapeutic agent, such as docetaxel, and at least one corticosteroid, such as, for example, prednisone. In one embodiment, the 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, is for administration with docetaxel and prednisone.
- Futher disclosed is a method for treating prostate cancer (preferably CRPC, more preferably mCRPC, and in particular early mCRPC associated with alkaline phosphatase (ALP) levels at baseline equal to or lower than 250 IU/L, and/or with a Halabi prognosis score (H) at baseline equal to or lower than 45) in a subject in need thereof as defined above, comprising administering to the subject a 2-aminoarylthiazole derivative, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof as described above.
- In one embodiment, the method is for treating early mCRPC as defined herein.
- In one embodiment, the method comprises administering a therapeutically effective dose of 2-aminoarylthiazole derivative as described above, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof.
- In one embodiment, the method comprises administering at least one further pharmaceutically active agent as described herein. In one embodiment, said at least one further pharmaceutically active agent is selected from chemotherapeutic agents and corticoids.
- The invention is as defined in the claims. Also disclosed is a pharmaceutical composition for treating or for use in the treatment of prostate cancer (preferably CRPC, more preferably mCRPC, and in particular early mCRPC associated with alkaline phosphatase (ALP) levels at baseline equal to or lower than 250 IU/L, and/or with a Halabi prognosis score (H) at baseline equal to or lower than 45) in a subject in need thereof as defined above, said pharmaceutical composition comprising a 2-aminoarylthiazole derivative, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof as described above and optionally at least one pharmaceutically acceptable excipient.
- In one embodiment, the pharmaceutical composition is for treating or for use in the treatment of early mCRPC as defined herein.
- In one embodiment, the pharmaceutical composition is for administration with at least one further pharmaceutically active agent as described herein. The pharmaceutical composition may be administered simultaneously, separately or sequentially with said at least one further pharmaceutically active agent. In one embodiment, said at least one further pharmaceutically active agent is selected from chemotherapeutic agents and corticoids.
- Further disclosed is the use of a 2-aminoarylthiazole derivative, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof as described above, for the manufacture of a medicament for the treatment of prostate cancer (preferably CRPC, more preferably mCRPC, and in particular early mCRPC associated with alkaline phosphatase levels at baseline equal to or lower than 250 IU/L, and/or with a Halabi prognosis score (H) at baseline equal to or lower than 45) in a subject in need thereof as defined above.
- Also disclosed is the use of a 2-aminoarylthiazole derivative, in particular masitinib, or a pharmaceutically acceptable salt thereof as described above, for the manufacture of a medicament for the treatment of early mCRPC as defined herein.
- In one embodiment, the medicament is for administration with at least one further pharmaceutically active agent as described herein. The medicament may be administered simultaneously, separately or sequentially with said at least one further pharmaceutically active agent. In one embodiment, said at least one further pharmaceutically active agent is selected from chemotherapeutic agents and corticoids.
- The present invention is further illustrated by the following examples.
- A prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel groups, phase 3 study was conducted to assess the efficacy and safety of masitinib in combination with docetaxel as compared to placebo in combination with docetaxel in first line metastatic castrate-resistant prostate cancer (mCRPC).
- The objective of the study was to assess the efficacy and safety of masitinib in combination with docetaxel as compared to docetaxel in combination with placebo in first line metastatic castrate-resistant prostate cancer (mCRPC). Efficacy was assessed based on the progression-free survival (PFS), measured in months.
- The patients recruited in the study consist of adult males suffering from prostate cancer who progressed to develop castration-resistant prostate cancer (CRPC) after castration treatment (reduction of androgens (e.g., testosterone, dihydrotestosterone (DHT)) by chemical or surgical means). These patients are considered to be patients in the first line metastatic castration-resistant prostate cancer (mCRPC).
- The patients recruited in the study were randomized in two groups with a ratio 1:1:
- Group 1: masitinib (6 mg/kg/day) + docetaxel (75mg/m2 6 cycles - 8 or 10 cycles possible) + prednisone according to usual practice;
- Group 2: placebo + docetaxel (75mg/m2 6 cycles - 8 or 10 cycles possible) + prednisone according to usual practice.
- Docetaxel was combined with prednisone as usual practice.
- Patients were centrally randomized to one of the two treatment groups by IWRS (Interactive Web Response System) according to minimization method.
- Inclusion criteria were:
- Patient aged ≥ 18 years old, with histologically or cytologically confirmed metastatic castrate-resistant prostate cancer (medical or surgical castration: androgens deprivation by GnRH agonist or antagonist or patient with surgical castration; hormonal castration confirmed biologically (testosterone < 0.5ng/mL) with one of the following criteria:
∗If surgical castration is done than there is no requirement to perform testosterone test. - ∘ Pre-treated with abiraterone with progressed disease documented, OR
- ∘ With indication for initiating docetaxel administration (e.g., widespread visceral disease or rapidly progressive disease).
- o Hemoglobin ≥ 10 g/dL
- o Platelets (PTL) ≥ 75 × 109/L
- o AST (aspartate aminotransferase)/ALT (alanine aminotransferase) ≤ 3x upper limit of normal or ULN (≤ 5 x ULN in case of liver metastases)
- o Gamma glutamyl transferase (GGT) ≤ 2.5 x ULN (≤ 5 x ULN in case of liver metastases)
- o Bilirubin ≤ 1.5 x ULN (≤ 3 x ULN in case of liver metastasis)
- o Normal creatinine or if abnormal creatinine, creatinine clearance ≥ 50 mL/min (Cockcroft and Gault formula)
- o Urea ≤ 2 x ULN
- o Albumin > 1 x LLN (lower limit of normal)
- o Proteinuria < 30 mg/dL (1+) on the dipstick; in case of proteinuria ≥ 1+ on the dipstick, 24 hours proteinuria must be ≤ 1.5g/24h
- Exclusion criteria were:
- Patient who has been previously treated with chemotherapy.
- Patient with bone marrow irradiation > 40% within 12 months before baseline
- Patient treated for a cancer other than prostate cancer within 3 years before enrolment, with the exception of basal cell carcinoma (and pTa or pT1 tumors)
- Patient with active central nervous system (CNS) metastasis or with history of CNS metastasis
- Patient presenting with cardiac disorders defined by at least one of the following conditions:
- o Patient with recent cardiac history (within 6 months) of:
- Acute coronary syndrome
- Acute heart failure (class III or IV of the New York Heart Association (NYHA) classification)
- Significant ventricular arrhythmia (persistent ventricular tachycardia, ventricular fibrillation, resuscitated sudden death)
- o Patient with cardiac failure class III or IV of the NYHA classification
- o Patient with severe conduction disorders which are not prevented by permanent pacing (atrio-ventricular block 2 and 3, sino-atrial block)
- o Syncope without known etiology within 3 months
- o Uncontrolled severe hypertension, according to the judgement of the investigator, or symptomatic hypertension
- o Patient with recent cardiac history (within 6 months) of:
- Patient with an history of poor compliance or an history of drug/alcohol abuse, or excessive alcohol beverage consumption that would interfere with the ability to comply with the study protocol, or current or past psychiatric disease that might interfere with the ability to comply with the study protocol or give informed consent
- Patient under treatment with any anti-tumor therapy (any radiotherapy, chemotherapy, biologic or anti-androgen therapy except GnRH/LHRH analogs).
-
- As used herein, the Halabi prognosis score (H) is based on the method described by Halabi et al. (J Clin Oncol. 2003 Apr 1;21(7):1232-7) and is used as an estimate of patient survival. As described above, the mathematic formula is based on the measurement of visceral disease (yes or no, the value of this parameter being equal to 1 if the subject is affected with visceral disease, and 0 if he is not), initial Gleason score (the value being equal to 1 if the Gleason score measured for the subject ranges from 8 to 10, and 0 if the Gleason score is inferior to 8), ECOG (Eastern Cooperative Oncology Group) performance status (ranging from 0 to 2), prostate specific antigen (PSA) levels (PSA, measured in ng/mL), lactic acid dehydrogenase (LDH) levels (LDH, measured in IU/L), alkaline phosphatase (ALP) levels (ALP or AP, measured in IU/L) and hemoglobin (HB, measured in g/dL).
- In particular, the Halabi prognosis score (H) was calculated using the following procedure for a subject having an ECOG performance status of 0 or 1:
- VISCERAL1: enter if the patient has been diagnosed with visceral disease (Yes/ No) (VISCERAL n).
- ECOG1: enter the patient's ECOG value (0 versus 1 versus 2) (ecog_SCR).
- GLEASON11: enter the patient's Gleason value - should be a whole number from the range: [2-10] (QSSCORE).
- LDH1: enter the patient's LDH value - should be a decimal number from the range: [6-4000 IU/L] (ldh_SCR).
- AP1: enter the patient's Alkaline Phosphatase value (AP1) - should be a decimal number from the range: [10-2500 IU/L] (SCREEN_LOCALV)
- HB1: enter the patient's Hemoglobin value - should be a decimal number from the range: [10-20g/dl] (HEMO_SCR).
- PSA1: enter the patient's PSA value - should be a decimal number from the range: [0.0001-5000 ng/ml] (PSA_SCR).
- ECOG1 = 0 (i.e., ECOG 0)
- GLEASON11 = 1 (i.e., Gleason score 8-10)
- LDH1 = 184
- AP1 = 88
- PSA1 = 3.9
- VISCERAL1 = 1 (i.e., visceral disease)
- HB1 = 13.0
- The efficacy of masitinib for treating mCRPC was assessed based on the progression-free survival (expressed by the median progression-free survival measured in months ("Median"), accompanied by the related 95% confidence interval ("95% CI") and p-value), and on two parameters measured in the subject population. First, a hazard ratio (HR) is measured, corresponding to the probability of death when treated with masitinib (+ docetaxel + prednisone) over the probability of death when treated with placebo (+ docetaxel + prednisone). Thus, a HR < 1 indicates that the probability of death when treated with masitinib is lower than the probability of death when treated with placebo (and is thus indicative of a therapeutic benefit). Second, a "Risk benefit" is measured, allowing to assess the effect of masitinib in a specific subgroup, as compared to the mirror subgroup.
- The results obtained first demonstrate that the therapeutic benefit of masitinib is dependent on the alkaline phosphatase (ALP) levels measured at baseline in the subject, as shown in Tables 1-4 below.
Table 1: Masitinib treatment effect in terms of median PFS (in months) according to baseline ALP levels equal to or lower than 250 IU/L Targeted group Treatment group Number of Subjects Median [95% CI] P-value Log Rank Hazard Ratio (95% CI) Risk Benefit ALP ≤ 250 MASITINIB 225 6.3 [5.6; 7.6] 0.0272 0.79 [0.65; 0.96] 21% ALP ≤ 250 PLACEBO 225 5.4 [4.8; 6.0] ALP > 250 MASITINIB 130 4.2 [3.5; 5.5] 0.1306 1.20 [0.93; 1.55] ALP > 250 PLACEBO 132 5.5 [4.3; 6.1] Table 2: Masitinib treatment effect in terms of median PFS (in months) according to baseline ALP levels equal to or lower than 200 IU/L Targeted group Treatment group Number of Subjects Median [95% CI] P-value Log Rank Hazard Ratio (95% CI) Risk Benefit ALP ≤ 200 MASITINIB 178 6.9 [5.8; 7.9] 0.0126 0.73 [0.58;.91] 27% ALP ≤ 200 PLACEBO 176 5.6 [4.6; 6.2] ALP > 200 MASITINIB 177 4.4 [4.1; 5.5] 0.1753 1.17 0.94; 1.45] ALP > 200 PLACEBO 181 5.1 [4.4; 5.8] Table 3: Masitinib treatment effect in terms of median PFS (in months) according to baseline ALP levels equal to or lower than 150 IU/L Targeted group Treatment group Number of Subjects Median [95% CI] P-value Log Rank Hazard Ratio (95% CI) Risk Benefit ALP ≤ 150 MASITINIB 134 6.9 [5.6; 8.5] 0.0008 0.63 [0.48; 0.82] 37% ALP ≤ 150 PLACEBO 133 5.5 [4.6; 6.9] ALP > 150 MASITINIB 221 4.9 [4.2; 5.8] 0.229 1.14 [0.94; 1.39] ALP > 150 PLACEBO 224 5.1 [4.4; 5.8] Table 4: Masitinib treatment effect in terms of median PFS (in months) according to baseline ALP levels equal to or lower than 100 IU/L Targeted group Treatment group Number of Subjects Median [95% CI] P-value Log Rank Hazard Ratio (95% CI) Risk Benefit ALP ≤ 100 MASITINIB 59 9.0 [7.6; 10.7] 0.0022 0.53 [0.35; 0.79] 47% ALP ≤ 100 PLACEBO 72 6.9 [5.5; 7.9] ALP > 100 MASITINIB 296 5.4 [4.3; 5.9] 0.9943 1.02 [0.86; 1.22] ALP > 100 PLACEBO 285 4.9 [4.2; 5.6] - As shown in Table 1, patients with ALP levels at baseline equal to or lower than 250 IU/L show an increased response to masitinib. In addition, as shown in Tables 1-4, lower ALP levels at baseline are associated with an improved hazard ratio (reaching 0.53 for ALP levels at baseline equal to or lower than 100 IU/L) corresponding to an increased risk benefit (reaching 47% for ALP levels at baseline equal to or lower than 100 IU/L).
- Second, the results obtained demonstrate that the therapeutic benefit of masitinib is dependent on the Halabi score (H) measured at baseline in the subject, as shown in Table 5 below.
Table 5: Masitinib treatment effect in terms of median PFS (in months) according to the Halabi prognosis score (H) at baseline Targeted group Treatment group Number of Subjects Median [95% CI] P-value Log Rank Hazard Ratio (95% CI) Risk benefit H ≤ 15 MASITINIB 17 15 [6.2; 30.5] 0.0051 0.28 [0.10; 0.81] 72% PLACEBO 18 5.9 [3.7; 9.7] H> 15 MASITINIB 338 5.5 [4.8; 6.2] 0.7264 0.99 [0.84; 1.16] 1% PLACEBO 339 5.3 [4.8; 5.8] H ≤ 16 MASITINIB 29 9.0 [5.5; 21.2] 0.0089 0.35 [0.16; 0.77] 65% PLACEBO 24 6.2 [4.9; 9.7] H> 16 MASITINIB 326 5.5 [4.8; 6.2] 0.8063 1.00 [0.85; 1.17] 0% PLACEBO 333 5.1 [4.8; 5.8] H ≤ 17 MASITINIB 41 7.0 [5.5; 14.5] 0.0229 0.49 [0.28; 0.87] 51% PLACEBO 35 7.3 [4.9; 9.7] H> 17 MASITINIB 314 5.5 [4.8; 6.2] 0.8357 1.00 [0.85; 1.18] 0% PLACEBO 322 5.0 [4.6; 5.7] H ≤ 18 MASITINIB 50 7.0 [5.5; 11.8] 0.0152 0.54 [0.33; 0.87] 46% PLACEBO 43 6.2 [4.9; 8.3] H> 18 MASITINIB 305 5.5 [4.8; 6.1] 0.9071 1.00 [0.85; 1.19] 0% PLACEBO 314 5.0 [4.6; 5.7] H ≤ 19 MASITINIB 70 6.9 [5.6; 9.0] 0.076 0.69 [0.48; 1.00] 31% PLACEBO 64 5.9 [4.2; 7.6] H> 19 MASITINIB 285 5.4 [4.2; 6.1] 0.8777 1.00 [0.84; 1.19] 0% PLACEBO 293 5.1 [4.8; 5.8] H ≤ 20 MASITINIB 86 7.0 [5.8; 9.7] 0.0145 0.65 [0.46; 0.90] 36% PLACEBO 84 6.2 [4.9; 7.6] H>20 MASITINIB 269 4.9 [4.2; 5.9] 0.8172 1.04 [0.87; 1.24] -4% PLACEBO 273 4.9 [4.4; 5.6] H ≤ 21 MASITINIB 101 7.0 [5.6; 8.9] 0.0066 0.65 [0.48; 0.88] 35% PLACEBO 97 5.8 [4.9; 7.0] H>21 MASITINIB 254 4.9 [4.2; 5.8] 0.6164 1.07 [0.89; 1.28] -7% PLACEBO 260 4.9 [4.4; 5.8] H ≤ 22 MASITINIB 116 6.9 [5.6; 8.5] 0.0034 0.65 [0.49; 0.87] 35% PLACEBO 115 5.9 [4.9; 6.9] H>22 MASITINIB 239 4.9 [4.2; 5.8] 0.4837 1.09 [0.90; 1.32] -9% PLACEBO 242 4.9 [4.2; 5.6] H ≤ 27 MASITINIB 203 6.5 [5.5; 7.6] 0.0099 0.75 [0.61; 0.93] 25% PLACEBO 203 5.6 [4.9; 6.2] H>27 MASITINIB 152 4.8 [4.1; 5.8] 0.1129 1.20 [0.95; 1.51] -20% PLACEBO 154 4.9 [4.2; 6.0] H ≤ 33 MASITINIB 265 6.4 [5.6; 7.6] 0.0187 0.81 [0.67; 0.97] 19% PLACEBO 269 5.6 [4.9; 6.0] H>33 MASITINIB 90 4.1 [3.4; 4.9] 0.0297 1.34 [0.98; 1.82] -34% PLACEBO 88 5.0 [4.2; 6.0] - As shown in Table 5, patients with a Halabi prognosis score (H) at baseline equal to or lower than 33 show an increased response to masitinib. In addition, the therapeutic benefit of masitinib increases when the Halabi score (H) at baseline decreases.
- Moreover, and as shown in Tables 6-10, the therapeutic benefit of masitinib is increased in patients presenting both low ALP levels measured at baseline (i.e., ALP levels at baseline equal to or lower than 250 IU/L), and a low Halabi score (H) measured at baseline (i.e., a Halabi prognosis score (H) at baseline equal to or lower than 33).
Table 6: Masitinib treatment effect in terms of median PFS (in months) according to baseline ALP levels equal to or lower than 250 IU/L and to a Halabi prognosis score (H) at baseline equal to or lower than 18 Targeted group Treatment group Number of Subjects Median [95% CI] P-value Log Rank Hazard Ratio (95% CI) Risk benefit ALP ≤ 250 and H ≤ 18 MASITINIB 49 7.7 [5.5; 11.8] 0.0098 0.52 [0.32; 0.84] 48% PLACEBO 41 5.9 [4.2; 7.6] ALP ≤ 250 and H> 18 MASITINIB 176 6.2 [5.4; 7.6] 0.2513 0.87 [0.69, 1.08] PLACEBO 184 4.9 [4.2; 6.0] ALP > 250 and H ≤ 18 MASITINIB 1 3.4 0.1573 Not applicable PLACEBO 2 10 [9.9; 10.4] ALP > 250 and H> 18 MASITINIB 129 4.3 [3.5; 5.5] 0.1647 1.19 [0.92; 1.53] PLACEBO 130 5.5 [4.2; 5.9] Table 7: Masitinib treatment effect in terms of median PFS (in months) according to baseline ALP levels equal to or lower than 250 IU/L and to a Halabi prognosis score (H) at baseline equal to or lower than 19 Targeted group Treatment group Number of Subjects Median [95% CI] P-value Log Rank Hazard Ratio (95% CI) Risk benefit ALP ≤ 250 and H ≤ 19 MASITINIB 66 6.9 [5.6; 8.9] 0.0295 0.66 [0.45; 0.96] 34% PLACEBO 61 5.6 [4.2; 7.5] ALP ≤ 250 and H> 19 MASITINIB 159 6.1 [4.8; 7.6] 0.2548 0.86 [0.68; 1.09] PLACEBO 164 4.9 [4.2; 6.0] ALP > 250 and H ≤ 19 MASITINIB 4 9.2 [2.3; 20.5] 0.4752 Not applicable PLACEBO 3 10 [9.9; 35.3] ALP > 250 and H> 19 MASITINIB 126 4.2 [3.5; 5.4] 0.1841 1.18 [0.91; 1.52] PLACEBO 129 5.3 [4.2; 5.9] Table 8: Masitinib treatment effect in terms of median PFS (in months) according to baseline ALP levels equal to or lower than 250 IU/L and to a Halabi prognosis score (H) at baseline equal to or lower than 20 Targeted group Treatment group Number of Subjects Median [95% CI] P-value Log Rank Hazard Ratio (95% CI) Risk benefit ALP ≤ 250 and H ≤ 20 MASITINIB 81 7.0 [5.6; 9.0] 0.0057 0.62 [0.44; 0.87] 38% PLACEBO 80 5.9 [4.9; 7.5] ALP ≤ 250 and H>20 MASITINIB 144 5.8 [4.4; 7.6] 0.4607 0.90 [0.70; 1.15] PLACEBO 145 4.9 [4.1; 6.0] ALP > 250 and H ≤ 20 MASITINIB 5 13 [2.3; 20.5] 0.7166 1.78 [0.28; 11.49] PLACEBO 4 10 [7.0; 35.3] ALP > 250 and H>20 MASITINIB 125 4.2 [3.5; 5.4] 0.1598 1.19 [0.92; 1.54] PLACEBO 128 5.3 [4.2; 5.9] Table 9: Masitinib treatment effect in terms of median PFS (in months) according to baseline ALP levels equal to or lower than 250 IU/L and to a Halabi prognosis score (H) at baseline equal to or lower than 21 Targeted group Treatment group Number of Subjects Median [95% CI] P-value Log Rank Hazard Ratio (95% CI) Risk benefit ALP ≤ 250 and H ≤ 21 MASITINIB 95 7.0 [5.6; 8.9] 0.0027 0.62 [0.45; 0.85] 38% PLACEBO 91 5.7 [4.9; 7.0] ALP ≤ 250 and H>21 MASITINIB 130 5.8 [4.2; 7.2] 0.6706 0.94 [0.72; 1.22] PLACEBO 134 4.9 [3.9; 6.0] ALP > 250 and H ≤ 21 MASITINIB 6 8.3 [2.3; 20.5] 0.7598 0.99 [0.25; 3.88] PLACEBO 6 8.4 [4.2; 35.3] ALP > 250 and H>21 MASITINIB 124 4.2 [3.5; 5.4] 0.1613 1.19 [0.92; 1.54] PLACEBO 126 5.3 [4.2; 5.9] Table 10: Masitinib treatment effect in terms of median PFS (in months) according to baseline ALP levels equal to or lower than 250 IU/L and to a Halabi prognosis score (H) at baseline equal to or lower than 22 Targeted group Treatment group Number of Subjects Median [95% CI] P-value Log Rank Hazard Ratio (95% CI) Risk benefit ALP ≤ 250 and H ≤ 22 MASITINIB 110 6.9 [5.6; 8.3] 0.0016 0.63 [0.47; 0.85] 37% PLACEBO 107 5.8 [4.9; 6.7] ALP ≤ 250 and H>22 MASITINIB 115 5.8 [4.2; 7.2] 0.8419 0.97 [0.73; 1.28] PLACEBO 118 4.8 [3.6; 6.0] ALP > 250 and H ≤ 22 MASITINIB 6 8.3 [2.3; 20.5] 0.9411 0.88 [0.26; 2.96] PLACEBO 8 7.5 [3.5; 10.4] ALP > 250 and H>22 MASITINIB 124 4.2 [3.5; 5.4] 0.1565 1.20 [0.92; 1.55] PLACEBO 124 5.3 [4.2; 5.9] - Similar results were obtained in patients presenting ALP levels at baseline lower than 250 IU/L. For example, in the group of patients presenting ALP levels at baseline equal to or lower than 200 IU/L and a Halabi prognosis score (H) equal to or lower than 18 at baseline, the measured hazard ratio is of about 0.5 and the risk benefit of about 50%. In the group of patients with ALP levels at baseline equal to or lower than 150 IU/L and a Halabi prognosis score (H) equal to or lower than 18 at baseline, these values are respectively of 0.46 and 55%, and of 0.46 and 56% in the group of patients with ALP levels at baseline equal to or lower than 100 IU/L and a Halabi prognosis score (H) equal to or lower than 18 at baseline.
- Altogether, these data demonstrate a strong benefit effect of masitinib for treating mCRPC in patients presenting low ALP levels at baseline (e.g., equal to or lower than 250 IU/L) and/or a low Halabi score (H) at baseline (e.g., equal to or lower than 33).
- Patient with evidence of progressive metastatic disease. Disease progression at trial enrolment is based on progression in at least one variable as described in the Prostate Cancer Clinical Trials Working Group (PCWG2) definition of response and progression for disease manifestations in prostate cancer (Scher et al. J Clin Oncol. 2008;26:1148-1159):
Variable | Definition of Response and Progression |
PSA (prostate-specific antigen) | • Favorable effect on PSA may be delayed for 12 weeks or more. An effort is made not to discontinue therapy solely on the basis of a rise in PSA in the absence of other indicators of disease progression. |
• Ignore early rises (prior to 12 weeks) in determining PSA response. | |
• Record the percent change from baseline (rise or fall) at 12 weeks, and separately, the maximal change (rise or fall) at any time using a waterfall plot. | |
Response | |
Decline of ≥ 50% from baseline confirmed by a second value at least 3 weeks later. | |
Time to PSA progression is defined according to PCWG2 | |
• For patients whose PSA has initially decreased, progression is defined as the first PSA increase that is ≥ 25% above the nadir and ≥ 2ng/mL above the nadir and which is confirmed after 3 or more weeks later sequentially. | |
• For patients whose PSA has not decreased, progression is defined as the first PSA increase that is ≥ 25% above the nadir and ≥ 2ng/mL above the baseline and which is confirmed after 3 or more weeks later sequentially. | |
As per PCWG2, increase in PSA within the first 12 weeks of treatment will not be considered as progression. | |
Soft-tissue lesion (nodal and visceral) | Use -RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 (Eisenhauer et al. European Journal of Cancers 45: 228-247, 2009) with caveats |
• Only report changes in lymph nodes that were ≥ 2 cm in diameter at baseline. | |
• Record changes in nodal and visceral soft tissue sites separately. | |
• Record complete elimination of disease at any site separately. | |
• Confirm responses with second scan 6-8 weeks later; for progression, no confirmation is needed. | |
Response | |
Use RECIST 1.1 for response evaluation of nodal and visceral lesions. | |
Progression | |
Use RECIST 1.1 criteria for progression. | |
Bone | Use -RECIST 1.1 and PCWG2 |
Response | |
Use RECIST 1.1 and PCWG2 | |
Progression | |
The occurrence of 2 new bone lesions. Use RECIST 1.1 and PCWG2. | |
Confirmation is needed at week 12. | |
Symptoms (pain and analgesic consumption) | • Consider independently of other outcome measures. |
• Document pain and analgesia at baseline and measure repeatedly at 4-week intervals. | |
• Ignore early changes (≤12 weeks) in pain in absence of compelling evidence of disease progression. | |
• Confirm response or progression of pain end points 3 weeks later. | |
Response | |
Reduction in the present pain intensity (PPI) score by two points without an increase in the analgesic score, or reduction of at least 50% in the analgesic score without an increase in the PPI score. Response has to be maintained for at least three weeks. | |
Progression | |
Increase PPI score of at least one point from nadir and an increase from baseline of at least 25% in analgesic score, or a requirement for palliative radiotherapy and confirmed three weeks later. | |
Increase in PPI score within the first 12 weeks of treatment will not be considered as progression. |
- Patient with ECOG ≤ 1
- Patient with adequate organ function:
Absolute neutrophil count (ANC) ≥ 1.5 × 109/L
- Patient with life expectancy > 3 months
- Patient with BMI > 18 kg/m2 and patient weight > 40 kg
- Male patient with a female partner of childbearing potential who agrees to use a highly effective method of contraception and an acceptable method of contraception by his female partner during the study and for 3 months after the last treatment intake or who agrees to use an acceptable method of contraception and a highly effective method of contraception by his female partner during the study and for 3 months after the last treatment intake.
Claims (15)
- Masitinib, or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of metastatic castrate-resistant prostate cancer (mCRPC) in a subject in need thereof, wherein said subject suffers from early mCRPC associated (i) with alkaline phosphatase (ALP) levels at baseline equal to or lower than 250 IU/L, or (ii) with a Halabi prognosis score (H) at baseline equal to or lower than 33, or (iii) with ALP levels at baseline equal to or lower than 250 IU/L and with a Halabi prognosis score (H) at baseline equal to or lower than 33, and wherein the Halabi prognosis score (H) is calculated using the following formula: H = [0.392 × (2 if Eastern Cooperative Oncology Group (ECOG)=2, 1 if ECOG=1, 0 if ECOG=0)] + [0.335 × (1 if Gleason Score in [8-10], 0 if Gleason Score <8)] + [exp (0.312 × log(lactic acid dehydrogenase) + 0.211 × log(alkaline phosphatase) + 0.093 × log(prostate specific antigen)] + [0.161 × (1 if presence of visceral disease, else 0)] - [0.082 × hemoglobin].
- Masitinib, or the pharmaceutically acceptable salt or solvate thereof, for use according to claim 1, wherein said subject has ALP levels at baseline equal to or lower than 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, or 100 IU/L.
- Masitinib, or the pharmaceutically acceptable salt or solvate thereof, for use according to claim 1 or 2, wherein said subject has ALP levels at baseline equal to or lower than 200 IU/L.
- Masitinib, or the pharmaceutically acceptable salt or solvate thereof, for use according to any one of claims 1 to 3, wherein said subject has ALP levels at baseline equal to or lower than 150 IU/L.
- Masitinib, or the pharmaceutically acceptable salt or solvate thereof, for use according to any one of claims 1 to 4, wherein said subject has ALP levels at baseline equal to or lower than 100 IU/L.
- Masitinib, or the pharmaceutically acceptable salt or solvate thereof, for use according to any one of claims 1 to 5, wherein said subject has a Halabi prognosis score (H) at baseline equal to or lower than 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15.
- Masitinib, or the pharmaceutically acceptable salt or solvate thereof, for use according to any one of claims 1 to 6, wherein said subject has a Halabi prognosis score (H) at baseline equal to or lower than 22.
- Masitinib, or the pharmaceutically acceptable salt or solvate thereof, for use according to any one of claims 1 to 7, wherein said subject received hormone therapy selected from the group consisting of luteinizing hormone-releasing hormone (LHRH) agonists (also known as gonadotropin-releasing hormone (GnRH) agonists), LHRH antagonists (also known as GnRH antagonists), and abiraterone.
- Masitinib, or the pharmaceutically acceptable salt or solvate thereof, for use according to any one of claims 1 to 8, wherein the pharmaceutically acceptable salt of masitinib is masitinib mesilate.
- Masitinib, or the pharmaceutically acceptable salt or solvate thereof, for use according to any one of claims 1 to 9, wherein said masitinib, or the pharmaceutically acceptable salt or solvate thereof, is for administration at a dose ranging from 1 to 12 mg/kg/day (mg per kilo body weight per day), preferably at a dose ranging from 3 to 6 mg/kg/day.
- Masitinib, or the pharmaceutically acceptable salt or solvate thereof, for use according to any one of claims 1 to 10, wherein said masitinib, or the pharmaceutically acceptable salt or solvate thereof, is for administration at a dose of 6 mg/kg/day.
- Masitinib, or the pharmaceutically acceptable salt or solvate thereof, for use according to any one of claims 1 to 11, wherein said masitinib, or the pharmaceutically acceptable salt or solvate thereof, is for oral administration.
- Masitinib, or the pharmaceutically acceptable salt or solvate thereof, for use according to any one of claims 1 to 12, wherein said masitinib, or the pharmaceutically acceptable salt or solvate thereof, is for administration in two daily intakes.
- Masitinib, or the pharmaceutically acceptable salt or solvate thereof, for use according to any one of claims 1 to 13, wherein said masitinib, or the pharmaceutically acceptable salt or solvate thereof, is for administration with at least one further pharmaceutically active agent.
- Masitinib, or the pharmaceutically acceptable salt or solvate thereof, for use according to claim 14, wherein said at least one further pharmaceutically active agent is selected from chemotherapeutic agents and corticoids.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21305643 | 2021-05-17 | ||
PCT/EP2022/063361 WO2022243339A1 (en) | 2021-05-17 | 2022-05-17 | Masitinib for the treatment of castrate-resistant prostate cancer |
Publications (3)
Publication Number | Publication Date |
---|---|
EP4175639A1 EP4175639A1 (en) | 2023-05-10 |
EP4175639C0 EP4175639C0 (en) | 2023-10-25 |
EP4175639B1 true EP4175639B1 (en) | 2023-10-25 |
Family
ID=76217785
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP22733858.9A Active EP4175639B1 (en) | 2021-05-17 | 2022-05-17 | Masitinib for the treatment of castrate-resistant prostate cancer |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230321081A1 (en) |
EP (1) | EP4175639B1 (en) |
KR (1) | KR20240008875A (en) |
CN (1) | CN117337177A (en) |
AU (1) | AU2022276086A1 (en) |
BR (1) | BR112023023934A2 (en) |
CA (1) | CA3217490A1 (en) |
ES (1) | ES2963706T3 (en) |
IL (1) | IL308088A (en) |
PL (1) | PL4175639T3 (en) |
WO (1) | WO2022243339A1 (en) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0313165B8 (en) | 2002-08-02 | 2021-05-25 | Ab Science | 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors |
ES2522169T3 (en) | 2007-02-13 | 2014-11-13 | Ab Science | Polymorph form of 2-amino (nitroaryl) thiazole derivative |
WO2015185958A1 (en) * | 2014-06-02 | 2015-12-10 | Ab Science | Use of an inhibitor of kinase activity, particularly masitinib, for treatment of prostate cancer |
-
2022
- 2022-05-17 BR BR112023023934A patent/BR112023023934A2/en unknown
- 2022-05-17 ES ES22733858T patent/ES2963706T3/en active Active
- 2022-05-17 KR KR1020237042195A patent/KR20240008875A/en unknown
- 2022-05-17 PL PL22733858.9T patent/PL4175639T3/en unknown
- 2022-05-17 WO PCT/EP2022/063361 patent/WO2022243339A1/en active Application Filing
- 2022-05-17 EP EP22733858.9A patent/EP4175639B1/en active Active
- 2022-05-17 US US18/040,884 patent/US20230321081A1/en active Pending
- 2022-05-17 IL IL308088A patent/IL308088A/en unknown
- 2022-05-17 CA CA3217490A patent/CA3217490A1/en active Pending
- 2022-05-17 CN CN202280035912.5A patent/CN117337177A/en active Pending
- 2022-05-17 AU AU2022276086A patent/AU2022276086A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
PL4175639T3 (en) | 2024-02-05 |
AU2022276086A1 (en) | 2023-11-16 |
CN117337177A (en) | 2024-01-02 |
EP4175639C0 (en) | 2023-10-25 |
WO2022243339A1 (en) | 2022-11-24 |
ES2963706T3 (en) | 2024-04-01 |
EP4175639A1 (en) | 2023-05-10 |
US20230321081A1 (en) | 2023-10-12 |
IL308088A (en) | 2023-12-01 |
BR112023023934A2 (en) | 2024-01-30 |
KR20240008875A (en) | 2024-01-19 |
CA3217490A1 (en) | 2022-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11413258B2 (en) | Methods for treating cancer | |
KR102293847B1 (en) | Use of masitinib for the treatment of a subpopulation of patients with amyotrophic lateral sclerosis | |
JP2013525291A (en) | Organic compounds for use in the treatment of liver cancer | |
JP2015536986A (en) | Combination therapy | |
US20180311236A1 (en) | Use of masitinib and other mast cell inhibitors for treatment of parkinson's disease | |
EP2849756A1 (en) | Dosage regimen for a pi-3 kinase inhibitor | |
AU2022211877A1 (en) | Compositions for treating or preventing vasomotor symptoms | |
EP4175639B1 (en) | Masitinib for the treatment of castrate-resistant prostate cancer | |
US20230355618A1 (en) | Raf inhibitor for treating low grade glioma | |
JP2024518110A (en) | Masitinib for the treatment of castration-resistant prostate cancer | |
WO2021237273A1 (en) | Methods of treating pulmonary fibrosis | |
JP2017528517A (en) | Methods for treating hyperhidrosis | |
WO2023174314A1 (en) | Use and treatment method of azetidine derivative | |
CA3000894A1 (en) | Treatment of severe systemic mastocytosis with masitinib |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20230202 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20230519 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602022000793 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
U01 | Request for unitary effect filed |
Effective date: 20231103 |
|
U07 | Unitary effect registered |
Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT SE SI Effective date: 20231108 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2963706 Country of ref document: ES Kind code of ref document: T3 Effective date: 20240401 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240126 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240225 |